

1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND
THE THERAPEUTIC USE THEREOF

The present invention relates to
1-aminophthalazine derivatives, to their preparation
5 and to their therapeutic application.

The search for antagonists of the MCH
(Melatonin-Concentrating Hormone) receptor 1, the MCH₁
receptor, has aroused the interest of many
pharmaceutical companies. A certain number of patent
10 applications have been filed, among which mention may
be made of WO 01/21577 (Takeda), WO 02/06245 (Synaptic)
and WO 03/106452 (Millennium). A certain number of
publications have appeared, among which is Ma V.V. et
al. (Amgen) 224th Nat. Meeting ACS Boston. Poster MEDI
15 343 (21.08.2002).


In the last ten years, it has been
demonstrated that many neuropeptides are involved in
the central regulations governing eating behaviour and
also the energy balance (Inui et al., TINS 1999; 22(2):
20 62-67). MCH is among these neuropeptides.

Two MCH receptors have recently been cloned:
the MCH₁ receptor, previously known as the SLC-1 or
GPR24 receptor (Chambers et al., Nature 1999; 400:
261-265), and the MCH₂ receptor, previously known as SLT
25 (Mori et al., Biochem Biophys Res Commun 2001; 283:
1013-1018).

There is thus real interest in finding novel compounds for modulating the activity of the MCH₁ receptor.

It has now been found that
 5 1-aminophthalazine-based compounds show high affinity and selectivity towards the MCH₁ receptor.

One subject of the present invention is compounds corresponding to formula (I)



10

- A represents a C₁₋₄-alkylene group optionally substituted with one or more groups R₉, which may be identical or different;
- B represents a C₁₋₄-alkylene group optionally substituted with one or more groups R₁₀, which may be identical or different;
- R₉ and R₁₀ each represent, independently of each other, a hydrogen atom or a C₁₋₅-alkyl group,
- or alternatively R₉ and R₁₀ together form a single bond or a C₁₋₄-alkylene group;
- L represents a single bond or a C₁₋₂-alkylene, -CH=CH- or -C≡C- group; the C₁₋₂-alkylene and -CH=CH- groups being optionally substituted with one or more C₁₋₂-alkyl

20

substituents; or alternatively L represents a cycloprop-1,2-diyl group;

• R_1 represents an aryl or a heteroaryl; the aryl and heteroaryl groups being optionally substituted with one
5 or more radicals Z, which may be identical or different;

• R_2 and R_3 represent, independently of each other, a hydrogen atom or a C_{1-3} -alkyl or C_{1-3} -fluoroalkyl group,
. or alternatively R_2 or R_3 form, together with the
10 carbon atom that bears them, a cycloprop-1,1-diyl group;

• R_4 represents a hydrogen atom or a C_{1-5} -alkyl, C_{1-3} -fluoroalkyl, C_{3-6} -cycloalkyl, C_{3-6} -cycloalkyl- C_{1-3} -alkylene, C_{1-3} -alkyl-O- C_{1-3} -alkylene, HO- C_{1-3} -alkylene or
15 C_{1-3} -alkyl-X- C_{1-3} -alkylene group in which X represents S, SO or SO_2 ,

. or alternatively R_4 represents an R_aR_bN - C_{1-3} -alkylene, aryl, aryl- C_{1-3} -alkylene, aryl-O-, aryl-O- C_{1-3} -alkylene, aryl- C_{1-3} -alkylene-O- C_{1-3} -alkylene,
20 heteroaryl or heteroaryl- C_{1-3} -alkylene group; the aryl, aryl- C_{1-3} -alkylene, aryl-O-, aryl-O- C_{1-3} -alkylene, heteroaryl and heteroaryl- C_{1-3} -alkylene groups being optionally substituted with one or more radicals Z, which may be identical or different;

25 • R_5 represents a hydrogen or halogen atom or a C_{1-5} -alkyl, C_{1-3} -fluoroalkyl, C_{1-5} -alkoxy, C_{1-3} -fluoroalkoxy, HO- C_{1-3} -alkylene, -CN or C_{1-3} -alkyl-X- group in which X

represents S, SO or SO₂,

. or alternatively R₅ represents an R_aR_bN-,
R_aR_bN-C₁₋₃-alkylene, aryl, aryl-C₁₋₃-alkylene, aryl-O- or
heteroaryl group; the aryl, aryl-C₁₋₃-alkylene, aryl-O-
5 and heteroaryl groups being optionally substituted with
one or more radicals Z, which may be identical or
different;

• R₆ represents a hydrogen or halogen atom or a C₁₋₅-
alkyl, C₁₋₃-fluoroalkyl, C₁₋₅-alkoxy, C₁₋₃-fluoroalkoxy,
10 -CN, R_aR_bN-, R_aR_bN-C₁₋₃-alkylene, aryl or heteroaryl
group; the aryl and heteroaryl groups being optionally
substituted with one or more radicals Z, which may be
identical or different;

• R₇ represents a hydrogen or halogen atom or a
15 C₁₋₅-alkyl, C₁₋₃-fluoroalkyl, C₁₋₅-alkoxy,
C₁₋₃-fluoroalkoxy, HO-C₁₋₃-alkylene, -CN or C₁₋₃-alkyl-X-
group in which X represents S, SO or SO₂,

. or alternatively R₇ represents an R_aR_bN-, R_aR_bN-
C₁₋₃-alkylene, R_aR_bNC(O)-, C₁₋₃-alkyl-C(O)-, aryl, aryl-O-
20 or heteroaryl group; the aryl, aryl-O- and heteroaryl
groups being optionally substituted with one or more
radicals Z, which may be identical or different;

• R₈ represents a hydrogen or halogen atom or a
C₁₋₅-alkyl, C₁₋₅-alkoxy or C₁₋₃-fluoroalkoxy group;

25 • Z represents a hydrogen or halogen atom or a
C₁₋₅-alkyl, C₁₋₃-fluoroalkyl, C₃₋₆-cycloalkyl,
C₃₋₆-cycloalkyl-C₁₋₃-alkylene, phenyl, C₁₋₅-alkoxy, C₁₋₃-

fluoroalkoxy, C₁₋₃-alkyl-O-C₁₋₃-alkylene, HO-C₁₋₃-alkylene, NO₂, -CN, C₁₋₃-alkyl-X- or C₁₋₃-alkyl-X-C₁₋₃-alkylene group in which X represents S, SO or SO₂,

. or alternatively Z represents an R_aR_bN-, R_aR_bN-C₁₋₃-alkylene, R_aR_bNC(O)-, C₁₋₃-alkyl-C(O)-, C₁₋₄-alkyl-CO₂- or C₃₋₆-cycloalkyl-C(O)- group,

. or alternatively Z represents an oxo radical,

. or alternatively two adjacent radicals Z

together form a C₁₋₃-alkylenedioxy group;

10 • R_a and R_b each represent, independently of each other, a hydrogen atom or a C₁₋₃-alkyl or C₁₋₃-alkyl-C(O)-group,

. or alternatively R_a and R_b form, together with the nitrogen atom that bears them, a heterocycle

15 optionally substituted with one or more C₁₋₃-alkyl or oxo groups;

it being understood that when R₂, R₃, R₅, R₆, R₇ and R₈ all represent a hydrogen atom, A and B both represent an ethylenyl group (-CH₂CH₂-) and L is a single bond, R₁ and R₄ cannot both represent an unsubstituted phenyl group.

The compounds of formula (I) may comprise one or more asymmetric carbon atoms. They may thus exist in enantiomeric or diastereoisomeric form. These

25 enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, form part of the invention.

The compounds of formula (I) may comprise one or more rings. They may thus exist in the form of axial/equatorial, or endo/exo, or cis/trans isomers. These isomers, and also mixtures thereof, form part of
5 the invention.

The compounds of formula (I) may comprise one or more olefinic functions. They may thus exist in the form of Z/E isomers. These isomers, and also mixtures thereof, form part of the invention.

10 The compounds of formula (I) may exist in the form of bases or of acid-addition salts. Such addition salts form part of the invention.

These salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of
15 other acids that are useful, for example, for purifying or isolating the compounds of formula (I) also form part of the invention.

The compounds of formula (I) may also exist in the form of hydrates and/or solvates, i.e. in the
20 form of associations or combinations with one or more water molecules and/or solvent. Such hydrates and solvates also form part of the invention.

In the context of the present invention, the following definitions apply:

25 - C_{t-z} in which t and z may take values from 1 to 6, a chain or a carbon-based ring possibly containing from t to z carbon atoms, for example C_{1-3} can characterize a

carbon-based chain containing from 1 to 3 carbon atoms;

- a halogen atom: a fluorine, a chlorine, a bromine or an iodine;

- an alkyl group: a linear or branched, saturated monovalent aliphatic group. Examples that may be mentioned include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, etc. groups;

- an alkylene group: a linear or branched saturated divalent aliphatic group. By way of example, a C₁₋₃-alkylene group represents a linear or branched divalent carbon-based chain of 1 to 3 carbon atoms, such as a methylenyl (-CH₂-), an ethylenyl (-CH₂CH₂-), a 1-methylethylenyl (-CH(CH₃)CH₂-), a propylenyl (-CH₂CH₂CH₂-), etc.;

- a cycloalkyl group: a saturated cyclic aliphatic group. Examples that may be mentioned include cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. groups;

- an alkoxy group: an alkyl-O- radical in which the alkyl group is as defined above;

- an alkylenedioxy group: an -O-alkylene-O- group, in which the alkylene group is as defined above.

Examples that may be mentioned include methylenedioxy, ethylenedioxy and propylenedioxy groups;

- a fluoroalkyl group: an alkyl group of which one or more hydrogen atoms have been replaced with a fluorine atom. Examples that may be mentioned include

CF₃-, CF₃CH₂-, etc. groups;

- a fluoroalkoxy group: an alkoxy group of which one or more hydrogen atoms have been replaced with a fluorine atom. Examples that may be mentioned include

5 CF₃O-, CHF₂O-, etc. groups;

- a heterocyclic group: a saturated 5- to 7-membered cyclic group comprising one or more hetero atoms such as nitrogen, oxygen or sulfur atoms. Examples that may be mentioned include pyrrolidinyl, piperidyl,

10 piperidonyl, morpholinyl, piperazinyl, N-methyl-piperazinyl, etc. groups;

- an aryl group: monocyclic or polycyclic aromatic system containing from 6 to 14 carbon atoms and preferably from 6 to 10 carbon atoms. When the system

15 is polycyclic, at least one of the rings is aromatic.

Examples that may be mentioned include phenyl, naphthyl, tetrahydronaphthyl, indanyl, etc. groups;


- a heteroaryl group: 5- to 14-membered and preferably 5- to 10-membered monocyclic or polycyclic

20 aromatic system comprising one or more hetero atoms such as nitrogen, oxygen or sulfur atoms. When the system is polycyclic, at least one of the rings is aromatic. The nitrogen atoms may be in the form of N-oxides. Examples of monocyclic heteroaryl groups that

25 may be mentioned include thiazolyl, thiadiazolyl, thienyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl,

pyrazolyl, pyrimidinyl and pyridazinyl groups. Examples of bicyclic heteroaryl groups that may be mentioned include indolyl, benzofuranyl, chromen-2-on-yl, benzimidazolyl, benzothienyl, benzotriazolyl, 5 benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, indazolyl, indoliziny, quinazolinyl, phthalazinyl, quinoxalinyl, naphthyridinyl, 2,3-dihydro-1H-indolyl, 2,3-dihydrobenzofuranyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl 10 groups.

In the general formula (I), the ring:



may be, for example, an azetidiny, pyrrolidinyl, piperidyl, azepanyl, 8-azabicyclo[3.2.1]octyl, 15 8-azabicyclo[3.3.1]nonanyl, decahydroisoquinolinyl or 3-azabicyclo[3.1.0]hexanyl group.

Among the compounds of formula (I) that are subjects of the invention, mention may be made of a first subgroup of compounds that are defined as 20 follows:

- A represents a C₁₋₄-alkylene group optionally substituted with one or more groups R₉, which may be identical or different;

- B represents a C₁₋₄-alkylene group optionally substituted with one or more groups R₁₀, which may be identical or different;
- R₉ and R₁₀ each represent a hydrogen atom, or
5 alternatively R₉ and R₁₀ together form a C₁₋₄-alkylene group;
- L represents a single bond or -CH=CH-;
- R₁ represents an aryl or a heteroaryl; the aryl and heteroaryl groups being optionally substituted with one
10 or more radicals Z, which may be identical or different;
- R₂ and R₃ represent, independently of each other, a hydrogen atom or a C₁₋₃-alkyl group;
- R₄ represents a hydrogen atom or a C₁₋₅-alkyl, C₃₋₆-
15 cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₃-alkylene, C₁₋₃-alkyl-O-C₁₋₃-alkylene, aryl, aryl-C₁₋₃-alkylene, aryl-C₁₋₃-alkylene-O-C₁₋₃-alkylene, heteroaryl or heteroaryl-C₁₋₃-alkylene group; the aryl, aryl-C₁₋₃-alkylene, heteroaryl and heteroaryl-C₁₋₃-alkylene groups being optionally
20 substituted with one or more radicals Z, which may be identical or different;
- R₅ represents a hydrogen atom or a C₁₋₅-alkyl, C₁₋₅-alkoxy or aryl group; the aryl group being optionally substituted with one or more radicals Z, which may be
25 identical or different;
- R₆ represents a hydrogen atom;

- R_7 represents a halogen atom or a C_{1-5} -alkyl group and more particularly a methyl, C_{1-5} -alkoxy and more particularly a methoxy or an aryl;
- R_8 represents a hydrogen atom;
- 5 • Z represents a hydrogen or halogen atom or a C_{1-5} -alkyl, C_{1-3} -fluoroalkyl, C_{3-6} -cycloalkyl, C_{3-6} -cycloalkyl- C_{1-3} -alkylene, phenyl, C_{1-5} -alkoxy, C_{1-3} -fluoroalkoxy, C_{1-3} -alkyl-O- C_{1-3} -alkylene, HO- C_{1-3} -alkylene, NO_2 , -CN, C_{1-3} -alkyl-X- or C_{1-3} -alkyl-X- C_{1-3} -alkylene group in which
- 10 X represents S, SO or SO_2 ,
 - . or alternatively Z represents an R_aR_bN -, R_aR_bN - C_{1-3} -alkylene, $R_aR_bNC(O)$ -, C_{1-3} -alkyl-C(O)- or C_{3-6} -cycloalkyl-C(O)- group,
 - . or alternatively Z represents an oxo radical,
 - 15 . or alternatively two adjacent radicals Z together form a C_{1-3} -alkylenedioxy group;
- R_a and R_b each represent, independently of each other, a hydrogen atom or a C_{1-3} -alkyl or C_{1-3} -alkyl-C(O)-group,
- 20 . or alternatively R_a and R_b form, together with the nitrogen atom that bears them, a heterocycle optionally substituted with one or more C_{1-3} -alkyl or oxo groups.

Among the compounds of formula (I) that are
 25 subjects of the invention, mention may be made of a second subgroup of compounds that are defined as follows:

- A represents a C₁₋₄-alkylene group optionally substituted with a group R₉;
- B represents a C₁₋₄-alkylene group optionally substituted with a group R₁₀;
- 5 • R₉ and R₁₀ each represent a hydrogen atom or R₉ and R₁₀ together form a C₁₋₄-alkylene group;
- L represents a single bond or -CH=CH-;
- R₁ represents an aryl optionally substituted with one or more radicals Z, which may be identical or
- 10 different;
- R₂ and R₃ represent, independently of each other, a hydrogen atom or a C₁₋₃-alkyl group;
- R₄ represents a hydrogen atom or a C₁₋₅-alkyl, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₃-alkylene, C₁₋₃-alkyl-O-
- 15 C₁₋₃-alkylene or aryl group and more particularly a phenyl, or a heteroaryl group and more particularly a thienyl or a pyridyl; the aryl and heteroaryl groups being optionally substituted with one or more radicals Z, which may be identical or different;
- 20 • R₅ represents a hydrogen atom;
- R₆ represents a hydrogen atom;
- R₇ represents a halogen atom, a methyl or a methoxy;
- R₈ represents a hydrogen atom;
- Z represents a hydrogen atom, a halogen atom or a
- 25 C₁₋₅-alkyl, C₁₋₅-alkoxy and more particularly methoxy, C₁₋₃-alkyl-O-C₁₋₃-alkylene, phenyl, HO-C₁₋₃-alkylene, -CN

or C₁₋₃-alkyl-X- group in which X represents a sulfur atom,

. or alternatively Z represents an R_aR_bN-, R_aR_bN-C₁₋₃-alkylene, R_aR_bNC(O)- or C₁₋₃-alkyl-C(O)- group,

5 . or alternatively Z represents an oxo radical,

. or alternatively two adjacent radicals Z together form a C₁₋₃-alkylenedioxy group, more particularly a methylenedioxy;

• R_a and R_b each represent, independently of each other,
10 a hydrogen atom or a C₁₋₃-alkyl or C₁₋₃-alkyl-C(O)- group.

In the context of the present invention the compounds of formula (I) in which at least one of the substituents R₅, R₆, R₇ or R₈ is other than a hydrogen
15 atom are more particularly suitable.

Among the compounds of formula (I) that are subjects of the invention, mention may be made especially of:

- 7-methoxy-4-(4-methoxyphenyl)-N-[8-(2-naphthyl-
20 methyl)-8-azabicyclo[3.2.1]oct-3-yl]phthalazin-1-amine
(compound 4);
- 7-methoxy-4-(4-methoxyphenyl)-N-[1-(2-naphthyl-
methyl)piperidin-4-yl]phthalazin-1-amine (compound 3);
- 7-methoxy-4-(3-methoxyphenyl)-N-[1-(2-naphthyl-
25 methyl)piperidin-4-yl]phthalazin-1-amine (compound 5);
- 7-methoxy-4-(2-methoxyphenyl)-N-[1-(2-naphthyl-
methyl)piperidin-4-yl]phthalazin-1-amine (compound 2);

- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-phenylphthalazin-1-amine (compound 1);
- 4-(4-methoxyphenyl)-7-methyl-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 9);
- 5 • 4-(3,4-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 10);
- N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride (compound 19);
- 10 • 4-ethyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 20);
- 4-benzyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 21);
- 7-methoxy-4-(methoxymethyl)-N-[1-(2-naphthylmethyl)-
- 15 piperidin-4-yl]phthalazin-1-amine hydrochloride (compound 24);
- N-[1-(1-benzofuran-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 26);
- 20 • N-[1-(3,4-dimethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 29);
- 7-methoxy-4-(4-methoxyphenyl)-N-{1-[(1-methyl-1H-indol-2-yl)methyl]piperidin-4-yl}phthalazin-1-amine (compound 31);
- 25 • 4-cyclopropyl-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine (compound 33);

- N-[1-(3-fluoro-4-methoxybenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 39);
- N-[1-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)-phthalazin-1-amine (compound 40);
- 4-(1,3-benzodioxol-5-yl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 42);
- 10 • 4-(4-chlorophenyl)-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine (compound 43);
- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-[4-(trifluoromethyl)phenyl]phthalazin-1-amine (compound 45);
- 15 • N-[1-(1-benzothien-2-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 48);
- 4-cyclopentyl-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 51);
- 20 • N-[1-(2,3-dihydro-1-benzofuran-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 54);
- N-[1-(2,3-dihydro-1H-inden-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 55);
- 25

- 7-methoxy-4-(4-methoxyphenyl)-N-{1-[1-(2-naphthyl)-ethyl]piperidin-4-yl}phthalazin-1-amine dihydrochloride (compound 56);
- N-[1-(1,3-benzothiazol-6-ylmethyl)piperidin-4-yl]-
5 7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 59);
- N-[1-(1-benzothien-5-ylmethyl)piperidin-4-yl]-
7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 60);
- 10 • N-[1-(1H-indol-3-ylmethyl)piperidin-4-yl]-7-methoxy-
4-(4-methoxyphenyl)phthalazin-1-amine (compound 65);
- 7-methoxy-4-(4-methylphenyl)-N-[1-(2-naphthyl-
methyl)piperidin-4-yl]phthalazin-1-amine (compound 66);
- 4-butyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-
15 4-yl]phthalazin-1-amine (compound 67);
- 7-methoxy-4-(4-methoxyphenyl)-N-{1-[(2E)-3-
phenylprop-2-en-1-yl]piperidin-4-yl}phthalazin-1-amine
dihydrochloride (compound 69);
- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-
20 phthalazin-1-amine (compound 70);
- 4-(cyclopropylmethyl)-7-methoxy-N-[1-(2-naphthyl-
methyl)piperidin-4-yl]phthalazin-1-amine (compound 71);
- N-[1-(3-fluoro-4-methylbenzyl)piperidin-4-yl]-
7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine
25 (compound 74);
- 7-methoxy-4-(4-methoxyphenyl)-N-[1-(4-methylbenzyl)-
piperidin-4-yl]phthalazin-1-amine (compound 75);

- 4-(4-fluorophenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 82);
- N-[1-(1H-indol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 87);
- 5 • 7-methoxy-4-[4-(methoxymethyl)phenyl]-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 88);
- 7-methoxy-N-[1-(4-methoxy-3-methylbenzyl)piperidin-4-yl]-4-(4-methoxyphenyl)phthalazin-1-amine
- 10 (compound 89);
- 7-methoxy-4-methyl-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 95);
- 4-(2,5-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine
- 15 dihydrochloride (compound 97);
- 7-methoxy-4-(4-methoxyphenyl)-N-[1-(quinolin-6-ylmethyl)piperidin-4-yl]phthalazin-1-amine (compound 99);
- 7-methoxy-4-(4-methoxyphenyl)-N-{1-[(1-methyl-1H-indol-5-yl)methyl]piperidin-4-yl}phthalazin-1-amine
- 20 (compound 100);
- 4-(2,4-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 102);
- 25 • 4-(3,5-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 103);

- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-
4-(2-phenylethyl)phthalazin-1-amine dihydrochloride
(compound 104);
- 4-{4-[(diethylamino)methyl]phenyl}-7-methoxy-N-[1-(2-
5 naphthylmethyl)piperidin-4-yl]phthalazin-1-amine
trihydrochloride (compound 105);
- 7-fluoro-4-(4-fluorophenyl)-N-[1-(2-naphthylmethyl)-
piperidin-4-yl]phthalazin-1-amine (compound 106);
- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-
10 4-pyridin-3-ylphthalazin-1-amine trihydrochloride
(compound 109);
- N-[1-(4-chlorobenzyl)piperidin-4-yl]-7-methoxy-
4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride
(compound 110);
- 15 • {4-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-
1-yl]amino}piperidin-1-yl)methyl]phenyl}methanol
dihydrochloride (compound 112);
- N-{1-[4-(aminomethyl)benzyl]piperidin-4-yl}-
7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine
20 trihydrochloride (compound 113);
- N-{4-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-
1-yl]amino}piperidin-1-yl)methyl]phenyl}acetamide
dihydrochloride (compound 114);
- 1-{4-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-
25 1-yl]amino}piperidin-1-yl)methyl]phenyl}ethanone
dihydrochloride (compound 121);

- N-[1-(1-benzofuran-5-ylmethyl)piperidin-4-yl]-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazin-1-amine dihydrochloride (compound 124);
- N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazin-1-amine dihydrochloride (compound 125);
- 6-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]-2H-chromen-2-one dihydrochloride (compound 127);
- 10 • N-[1-(1H-indol-6-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 129);
- 7-methoxy-N-[1-(4-methoxybenzyl)piperidin-4-yl]-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride (compound 130);
- 15 • N-[1-(4-ethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride (compound 132);
- N-[1-(1,3-benzothiazol-6-ylmethyl)piperidin-4-yl]-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazin-1-amine (compound 135);
- 20 • 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-(phenoxymethyl)phthalazin-1-amine dihydrochloride (compound 136);
- N-[1-(1H-benzimidazol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 138);
- 25

- 7-chloro-4-(4-methoxyphenyl)-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 143);
- 4-(4-bromophenyl)-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 145);
- N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(methoxymethyl)phthalazin-1-amine dihydrochloride (compound 146);
- 4-[(benzyloxy)methyl]-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 147);
- 7-methoxy-5-phenyl-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride (compound 17);
- 4-(hydroxymethyl)-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]-4-(phenoxyethyl)phthalazin-1-amine (compound 148);
- (-)-7-methoxy-4-(4-methoxyphenyl)-N-{1-[1-(2-naphthyl)ethyl]piperidin-4-yl}phthalazin-1-amine (compound 149);
- (+)-7-methoxy-4-(4-methoxyphenyl)-N-{1-[1-(2-naphthyl)ethyl]piperidin-4-yl}phthalazin-1-amine (compound 150);
- N-{1-[4-(dimethylaminomethyl)benzyl]piperidin-4-yl}-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine trihydrochloride (compound 151).

In accordance with the invention, the compounds of general formula (I) may be prepared according to the process illustrated by Scheme 1 below.

In Scheme 1, the starting compounds and the
5 reagents, when their mode of preparation is not described, are commercially available or described in the literature, or alternatively may be prepared according to methods described therein or that are known to those skilled in the art.

10 According to Scheme 1, the compound of general formula (I) is prepared from a compound of general formula (III), in which R_4 , R_5 , R_6 , R_7 and R_8 are as defined in the general formula (I), according to route A, by nucleophilic substitution of the chlorine
15 with the amine of the compound of general formula (II), in which R_1 , R_2 , R_3 , L, A and B are as defined in the general formula (I). This reaction may be performed by heating the compounds of general formulae (II) and (III) in an alcohol such as n-butanol in the presence
20 of ammonium chloride, according to the method described by Contreras et al. (J. Med. Chem. 2001, 44, 2707-2718), or alternatively may be catalysed with a transition metal such as palladium, for example in the form of tris(dibenzylideneacetone)dipalladium in the
25 presence of a ligand such as BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) and a base such as sodium tert-butoxide, according to the method


described by Wolfe et al. (J.A.C.S., 1996, 118, 7215-7216).

When R_3 is a hydrogen atom, the compound of general formula (I) may also be prepared, according to
5 route B, from the compound of general formula (Ib), in which A, B, R_4 , R_5 , R_6 , R_7 and R_8 are as defined in the general formula (I) and in which the nitrogen of the nitrogenous ring is not substituted, in particular via a reductive amination reaction with an aldehyde or a
10 ketone of general formula $R_1-L-C(O)R_2$, in which L, R_1 and R_2 are as defined in the general formula (I). This reaction may be performed, for example, in the presence of sodium triacetoxyborohydride in a solvent, for instance dichloromethane or 1,2-dichloroethane
15 according to one of the methods described in Abdel-Magid et al. (J. Org. Chem. 1996, 61, 3849-3862). The compound of general formula (Ib) is obtained by deprotection of the compound of general formula (Ia) that contains on the nitrogen of the nitrogenous ring a
20 protecting group PG. This protecting group may be, for example, a benzyl or a tert-butoxycarbonyl and the deprotection may be performed according to the methods cited in *Protective Groups in Organic Synthesis 3rd edition, John Wiley & Sons, New York 1999*. The compound
25 of general formula (Ia) is synthesized by reacting a compound of general formula (III) as defined above with a compound of general formula (IIa) according to the

processes already described previously for the compound (I).

The compound of general formula (IIa), when it is not commercial, may be prepared by analogy with
5 the methods described in the literature (Mach et al., J. Med. Chem. 1993, 36, 3707-3720, Dostert et al., Eur. J. Med. Chem. Ther. 1984, 19(2), 105-110).


The amine of formula (II), when it is not commercial, may be prepared by analogy with the methods
10 mentioned previously for (IIa) and also the methods described in the following publications: Moragues et al. (Farmaco. Ed. Sci. 1980, 35(11), 951-964) and Shum et al. (Nucleosides Nucleotides 2001, 20(4-7), 1067-1078).

Scheme 1

The 1-chlorophthalazine of general formula (III) may be obtained by heating the 2*H*-phthalazin-1-one of general formula (IV) in phosphoryl chloride for example.

5 La 2*H*-phthalazin-1-one of general formula (IV) may be prepared from an acid of 2-acylbenzoic type of general formula (V) by heating in an alcohol, for instance ethanol, in the presence of hydrazine hydrate for example.

10 The acid of 2-acyl-benzoic type of general formula (V) may be synthesized from an acid of 2-bromobenzoic type of general formula (VII) via halogen-metal exchange followed by reaction with an acid chloride of general formula (VI) or with a Weinreb
15 amide, of N-methoxy, N-methylamine type of formula (VI'):




(VI')

The halogen-metal exchange may be performed with *n*-butyllithium in tetrahydrofuran at -78°C. When R₄
20 represents a hydrogen atom, the acid chloride of general formula (VI) is replaced with dimethylformamide. The compounds of formula (VI') may be obtained from the compound of formula (VI) and N-methoxy-N-methylamine, especially according to the


method described by Weinreb (Tetrahedron Letters, (1981), 22(39): 3815-3818).

The acid of 2-acylbenzoic type of general formula (V) may also be obtained via other reactions, for instance the Friedel-Crafts reaction on a compound of general formula (VIII) in the presence of a compound of general formula (VI). This reaction is performed in the presence of aluminium chloride in a solvent such as dichloromethane.


A subject of the invention is also the compounds of formulae (V), (IV) and (III) below:



(V)



(IV)



(III)

15

in which R_4 , R_5 , R_6 , R_7 and R_8 are as defined above for the compounds of formula (I).

Examples of preparation of compounds of formulae (V), (IV) and (III) are given hereinbelow.

The compounds of formula (I) show high affinity and selectivity for the Melanin-Concentrating Hormone (MCH) receptor 1, MCH₁.

in vitro tests demonstrated the affinity of
5 the compounds for the MCH receptors and in particular MCH₁.

Since MCH is an important regulator of food intake, small non-peptide molecules capable of antagonizing its stimulatory action on the MCH₁
10 receptor constitute a therapy of choice for treating metabolic problems caused by obesity, but also bulimia. Specifically, the use of an MCH₁ receptor antagonist such as SNAP-7941 (described by Laboratoires Synaptic) confirms the important role of
15 MCH in regulating the energy balance and the development of obesity (Katsuura et al., Curr. Med. Chem. 2003; 3: 217-227).

The compounds according to the invention thus represent a therapy of choice for the treatment of
20 diseases presenting disorders of regulation of the energy balance and also for treating the development of obesity.

MCH is a functional antagonist of the melanocortin system, which counteracts the effects of
25 the latter on food intake and on the hypothalamo-pituitary-adrenal axis (Ludwig et al., Am. J. Physiol. 1998; 274: E627-E633). It is also involved in

regulating the hypothalamo-pituitary-adrenal axis and in the response to stress via the release of hypothalamic CRF (Kennedy et al., J Neuroendocrinol 2003; 15(3): 268-272).

5 The use of an MCH₁ receptor antagonist has recently confirmed the anxiogenic effect of MCH. Specifically, SNAP-7941 has an anxiolytic and/or antidepressant profile in various animal models such as social conflict and forced swimming in rats and also
10 maternal separation in guinea pigs (Katsuura et al., Curr. Med. Chem. 2003; 3: 217-227). MCH₁ receptor antagonist molecules are thus of therapeutic value in depression and/or anxiety.

 MCH appears to be involved in other
15 regulatory systems. By virtue of its localization in the testicles (Hervieu et al., Biology of Reproduction 1996; 5: 1161-1172) and in the hypothalamus (oestrogen-dependent, Viale et al., Peptides 1999; 20: 553-559) and by virtue of its stimulatory effects on sexual
20 activity in male rats (Gonzales et al., Peptides 1996; 17: 171-177) and its effects on the secretion of luteinizing hormone (Chiocchio et al., Biology of Reproduction 2001; 6: 1466-1472), MCH thus appears to play a role in reproductive functions.

25 It is also observed that MCH is involved in behaviour associated with cognitive functions by increasing the extinction of passive avoidance in rats,

suggesting that an MCH₁ receptor antagonist might be useful in the case of memory disorders (MacBride et al., Peptides 1994; 15(4): 757-759). Thus, the compounds according to the invention may constitute a therapy of
5 choice for treating memory disorders.

Thus, the compounds of the invention find their use in therapy, especially in the treatment of obesity, cellulitis, metabolic disorders and associated pathologies thereof such as diabetes, cardiovascular
10 disorders, syndrome X, in the treatment of stress-related pathologies such as anxiety and depression, and also in the treatment of any other disease involving dysfunction related to the MCH₁ receptor, whether at the central and/or peripheral level.

15 Thus, according to another of its aspects, a subject of the invention is medicinal products comprising a compound of formula (I) or an addition salt thereof with a pharmaceutically acceptable acid, or alternatively a hydrate or a solvate.

20 According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, at least one compound according to the invention. These pharmaceutical compositions comprise an effective dose
25 of at least one compound according to the invention, or a pharmaceutically acceptable salt, a hydrate or solvate of the said compound, and also at least one

pharmaceutically acceptable excipient. The said excipients are chosen according to the desired pharmaceutical form and mode of administration, from the usual excipients known to those skilled in the art.

5 In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active principle of formula (I)
10 above, or the possible salt, solvate or hydrate thereof, may be administered in unit administration form, as a mixture with standard pharmaceutical excipients, to man and animals for the prophylaxis or treatment of the above disorders or diseases.

15 The appropriate unit administration forms comprise oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms
20 for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants. For topical application, the compounds according to the invention may be used in creams, gels,
25 ointments or lotions.

By way of example, a unit administration form of a compound according to the invention in tablet form may comprise the following components:

	Compound according to the invention	50.0 mg
5	Mannitol	223.75 mg
	Sodium croscarmellose	6.0 mg
	Corn starch	15.0 mg
	Hydroxypropylmethylcellulose	2.25 mg
	Magnesium stearate	3.0 mg

10 The said unit forms are dosed to allow a daily administration of from 0.5 mg to 800 mg and more particularly from 0.5 mg to 200 mg of active principle per individual, depending on the galenical form.

 There may be cases where higher or lower
15 doses are appropriate: such doses are not outside the context of the invention. According to the usual practice, the appropriate dose for each patient is determined by the doctor according to the mode of administration, the weight and the response of the said
20 patient.

 According to another of its aspects, the present invention also relates to a method for treating the pathologies indicated above, which comprises the administration, to the patient, of an effective dose of
25 a compound according to the invention, or of a pharmaceutically acceptable salt, hydrate or solvate thereof.

The examples that follow describe the preparation of compounds in accordance with the invention. These examples are not limiting and serve merely to illustrate the present invention. The numbers
5 of the illustrated compounds refer to those given in Table I.

The methods for synthesizing the various intermediates for obtaining the compounds of the invention are described in the preparations. These
10 intermediates are all obtained according to methods that are well known to those skilled in the art.

The melting points (m.p.) are expressed in degrees Celsius. They were measured either using a Köffler apparatus (denoted (K) in the table) or using a
15 Mettler-Toledo FP62 apparatus (denoted (M) in the table) or using a Büchi B540 apparatus (denoted (B) in the table).

The analysis conditions by liquid chromatography coupled to mass spectrometry (LC/UV/MS)
20 are as follows:

For the liquid chromatography part:

- symmetry C18 (2.1 × 50 mm) 3.5 µm column
- Eluent A = H₂O + 0.005% TFA, pH = 3.14;
- Eluent B = CH₃CN + 0.005% TFA.
- 25 - gradient of from 100% A to 90% B in 10 minutes,
then elution with 90% B for 5 minutes.
- flow rate 0.4 ml/min

- injection of 2 μ L of solution at a concentration of 0.5 mg/ml in methanol
- the products are detected by UV at 210 nm.

For the mass spectrometry part:

- 5
- ionization mode: positive electrospray
 - sweep from 120 to 1500 amu.

The LC/MS analytical characteristics of the products are the m/z ratio of the ion MH^+ and the retention time (Rt) of the corresponding peak, observed
10 by UV and expressed in minutes.

The proton nuclear magnetic resonance (1H NMR) spectra were acquired at 250 MHz or at 300 MHz on Brüker machines. The abbreviations used to characterize the signals are as follows: s = singlet, m = multiplet,
15 d = doublet, t = triplet, q = quartet.

The optical rotations of the optically active products are characterized by their $[\alpha]_D^{t^\circ}$ (the concentrations c of the analyzed solutions are expressed in grams per 100 ml).

20 The quantification of the salts and solvates is determined with the aid of elemental analysis, metering of water by the Karl-Fischer technique and integration of the signals which are characteristic of the solvents in 1H NMR.

25 The compounds of the invention and their analytical characteristics (m.p., LC/MS, salts and solvates) are listed in table I.

Example 1: (compound 1)**7-Methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-
4-phenylphthalazin-1-amine****1.1. 2-benzoyl-5-methoxybenzoic acid**

5 A solution of 2-bromo-5-methoxybenzoic acid (5 g,
21.6 mmol) in 50 mL of THF is stirred under argon at
-78°C, and a 1.6 M solution of n-butyllithium in hexane
(29 mL, 45 mmol) is then added dropwise. The reaction
mixture is stirred for 1 hour at -78°C and benzoyl
10 chloride (3.2 g, 22.7 mmol) is then added dropwise. The
reaction mixture is stirred for 1 hour 30 minutes at
-78°C and then for 18 hours at room temperature. The
mixture is hydrolysed with 100 mL water and then washed
with ethyl acetate. The aqueous phase is acidified by
15 addition of 5 N hydrochloric acid and then extracted
with ethyl acetate. The organic phase obtained is
washed with brine and then dried over anhydrous sodium
sulfate. After filtration and evaporation under reduced
pressure, 5.4 g of a colourless oil are obtained, and
20 are used without purification.

1.2. 7-Methoxy-4-phenyl-2H-phthalazin-1-one

10.55 g (210 mmol) of hydrazine hydrate are added to a
solution of 5.4 g of 2-benzoyl-5-methoxy-benzoic acid
25 in 50 mL of ethanol, and the mixture is refluxed for 2
hours 30 minutes. The reaction medium is cooled and
then filtered. The precipitate obtained is washed with

ethanol and then dried under reduced pressure at 40°C.
740 mg of product are obtained in the form of a white solid.

m.p. = 215°C (Köfler block)

5 LC/MS: MH^+ = 253 (Rt = 7.05 minutes)

1H NMR δ in ppm (DMSO d_6): 3.97 (s, 3H); 7.48 (dd, J_1 = 8.8 Hz, J_2 = 2.7 Hz, 1H); 7.54 - 7.60 (m, 5H); 7.64 (d, J = 8.8 Hz, 1H); 7.75 (d, J = 2.7 Hz, 1H); 12.78 (s, 1H, NH).

10

1.3. 4-Chloro-6-methoxy-1-phenylphthalazine

7-Methoxy-4-phenyl-2H-phthalazin-1-one (740 mg, 2.9 mmol) is dissolved in 7 mL of phosphoryl chloride. The solution is heated at 80°C for 2 hours. The reaction
15 medium is cooled to room temperature and then poured slowly into 200 mL of water with stirring. The mixture is then stirred at 5°C, basified with 35% sodium hydroxide solution and then extracted with dichloromethane. The organic phase is washed with water
20 and then with brine and dried over anhydrous sodium sulfate. After filtration and evaporation under reduced pressure, 750 mg of product are obtained in the form of a beige-coloured powder.

m.p. = 199°C (Mettler FP62)

25 LC/MS: MH^+ = 271 (Rt = 7.89 minutes)

1H NMR δ in ppm (DMSO d_6): 4.06 (s, 3H); 7.60 - 7.64 (m, 4H); 7.67 - 7.72 (m, 3H); 7.95 (d, J = 9.2 Hz, 1H).

1.4. 7-Methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-4-phenylphthalazin-1-amine

373 mg (1.5 mmol) of 4-amino-1-(naphthalen-2-ylmethyl)piperidine and 69 mg (1.3 mmol) of ammonium chloride are added to a suspension of 350 mg (1.3 mmol) of 4-chloro-6-methoxy-1-phenylphthalazine in 6 mL of n-butanol. The mixture is heated at 135°C for 20 hours. The reaction medium is cooled to room temperature, hydrolysed with 50 mL of water and then basified to pH 10 with 1 N sodium hydroxide solution. The mixture is then extracted with ethyl acetate. The organic phase is washed with brine, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The residue obtained is purified by chromatography on a column of silica gel (solvent: 95/5 (v/v) dichloromethane/methanol). The yellow oil thus obtained forms a solid by trituration in isopropyl ether. After filtering and drying, 275 mg of product are obtained in the form of a beige-coloured powder.

m.p. = 121°C (Köfler block)
MH⁺ = 475 (Rt = 5.15 minutes)

¹H NMR δ in ppm (DMSO d 6): 1.69-1.83 (m, 2H); 2.08-2.25 (m, 4H); 2.96-3.01 (m, 2H); 3.71 (s, 2H); 3.99 (s, 3H); 4.27-4.37 (m, 1H); 7.06 (d, J = 7.5 Hz, 1H, NH); 7.44 (dd, J₁ = 8.8 Hz, J₂ = 2.7 Hz, 1H); 7.49 - 7.59 (m, 8H); 7.73 (d, J = 8.8 Hz, 1H); 7.79 (d, J = 2.7 Hz, 1H); 7.85 - 7.95 (m, 4H).

Example 2: (compound 11)

N-(1-benzylpiperidin-4-yl)-5,7-dimethoxy-4-(4-methoxyphenyl)phthalazin-1-amine

5

2.1. 3,5-dimethoxy-2-(4-methoxybenzoyl)benzoic acid

5.7 g (43 mmol) of aluminium chloride and then a solution of 4-methoxybenzoyl chloride (5.6 g, 33 mmol) are successively added to a solution of methyl 3,5-dimethoxybenzoate (6.4 g, 33 mmol) in 50 mL of dichloromethane, with stirring at room temperature. The mixture is stirred overnight at room temperature and is then poured into 200 mL of ice-cold water with stirring. The hydrolysed medium is extracted with dichloromethane. The organic phase is washed with saturated sodium hydrogen carbonate solution and then with water, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The crude extract is purified by chromatography on a column of silica gel (solvent: 3/1 (v/v) cyclohexane/ethyl acetate).

The methyl ester thus obtained is dissolved in 80 mL of methanol, and 17 mL of 2N sodium hydroxide solution are then added. The mixture is stirred overnight at room temperature, and then at 60°C for 3 hours. The methanol is then evaporated off under reduced pressure. The residual solution is diluted with 100 mL water,

acidified by addition of 2N hydrochloric acid and then extracted with dichloromethane. The organic phase is dried over anhydrous sodium sulfate and then evaporated under reduced pressure. A white solid is obtained

5 (5.4 g).

m.p. = 191°C. (Mettler FP62)

^1H NMR δ in ppm (DMSO d 6): 3.69 (s, 3H); 3.83 (s, 3H);
3.90 (s, 3H); 6.93 (d, $J = 2.2$ Hz, 1H); 9.91-7.03 (m,
2H); 7.09 (d, $J = 2.2$ Hz, 1H); 7.56-7.63 (m, 2H); 13.1
10 (s, 1H, COOH).

2.2. 5,7-dimethoxy-4-(4-methoxyphenyl)-2H-phthalazin-1-one.

This product is prepared from 3,5-dimethoxy-2-(4-methoxybenzoyl)benzoic acid, obtained in step 2.1,
15 according to the method described in step 1.2 of Example 1.

$\text{MH}^+ = 313$ ($\text{Rt} = 7.04$ minutes)

^1H NMR in ppm (DMSO d 6): 3.55 (s, 3H); 3.82 (s, 3H);
20 3.96 (s, 3H); 6.9-6.98 (m, 3H); 7.25-7.32 (m, 2H); 7.37
(d, 1H); 12.66 (s, NH).

2.3. 1-chloro-5,7-dimethoxy-4-(4-methoxyphenyl)phthalazine

25 This product is prepared from 5,7-dimethoxy-4-(4-methoxyphenyl)-2H-phthalazin-1-one, obtained in step

2.2, according to the method described in step 1.3 of Example 1.

MH⁺ = 331 (Rt = 7.73 minutes)

¹H NMR δ in ppm (DMSO d 6): 3.65 (s, 3H); 3.86 (s, 3H);
5 4.06 (s, 3H); 6.99-7.05 (m, 2H); 7.15 (d, J = 2.2 Hz, 1H); 7.22 (d, J = 2.2 Hz, 1H); 7.39-7.45 (m, 2H).

2.4. N-(1-benzylpiperidin-4-yl)-5,7-dimethoxy-4-(4-methoxyphenyl)phthalazin-1-amine

10 400 mg (1.2 mmol) of 4-chloro-6,8-dimethoxy-1-(4-methoxyphenyl)phthalazine dissolved in 5 mL of toluene, 276 mg (1.4 mmol) of 4-amino-1-benzylpiperidine, 163 mg (1.7 mmol) of sodium tert-butoxide, 6 mg (0.009 mmol) of BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl)
15 and 5.5 mg (0.006 mmol) of tris(dibenzylideneacetone)-dipalladium are successively introduced into a tube under argon. The tube is hermetically sealed and the mixture is stirred at 80°C for 24 hours.

After cooling to room temperature, the reaction medium
20 is hydrolysed with sodium hydrogen carbonate solution and then extracted with ethyl acetate. The organic phase is washed with water and with brine, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The residue obtained is purified by
25 chromatography on a column of silica gel (solvent: 95/5 (v/v) dichloromethane/methanol). The oily product obtained forms a solid by trituration in ethyl ether.

270 mg of product are obtained in the form of a beige-coloured powder.

m.p. = 168°C (Köffler)

MH⁺ = 485 (Rt = 4.82 minutes)

- 5 ¹H NMR δ in ppm (DMSO d 6): 1.67-1.76 (m, 2H); 2.04-2.17 (m, 4H); 2.90-2.94 (m, 2H); 3.54 (s, 5H); 3.82 (s, 3H); 3.98 (s, 3H); 4.20-4.30 (m, 1H); 6.84 (d, 1H, NH); 6.88-6.96 (m, 3H); 7.23-7.37 (m, 8H).

10 **Example 3: (compound 7)**

N-(1-benzylpiperidin-4-yl)-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine

3.1. N,4-dimethoxy-N-methylbenzamide

- 15 14.7 g (151 mmol) of N,O-dimethylhydroxylamine hydrochloride are added portionwise to a solution of 25 g (147 mmol) of 4-methoxybenzoyl chloride in 450 mL of dichloromethane, stirred at 0-5°C under nitrogen. 51 mL (370 mmol) of triethylamine are then added slowly
- 20 to the mixture stirred at 0-5°C. The orange-coloured reaction medium is stirred at room temperature for 3 hours. The mixture is hydrolysed with 250 mL of water and then extracted with dichloromethane. The organic phase is washed with 100 mL of 1N HCl, 150 mL of 1N
- 25 NaOH and then with water and brine. It is dried over anhydrous sodium sulfate, filtered and evaporated to dryness. 26.9 g of an orange-coloured oil are obtained,

and are purified on a column of silica, eluting with dichloromethane and then with a 95/5 dichloromethane/methanol mixture. 25.4 g of a yellow oil are obtained (89% yield).

5 LC/MS: $MH^+ = 196$ ($R_t = 5.21$ minutes)

1H NMR δ in ppm (DMSO d_6): 3.26 (s, 3H); 3.56 (s, 3H); 3.82 (s, 3H); 7.00 (d, $J=8.5$ Hz, 2H); 7.63 (d, $J=8.5$ Hz, 2H).

10 **3.2. 5-methoxy-2-(4-methoxybenzoyl)benzoic acid**

A solution of 18.5 g (80 mmol) of 2-bromo-5-methoxybenzoic acid in 150 mL of tetrahydrofuran is stirred under nitrogen at $-78^\circ C$ in a bath of cardice/acetone. 100 mL (160 mmol) of a 1.6M solution
15 of *n*-butyllithium in hexane are added dropwise over about 1 hour, while taking care to ensure that the temperature does not exceed $-70^\circ C$. About half way through the introduction, the formation of a beige-coloured precipitate that corresponds to the formation
20 of the lithium carboxylate is noted. After the addition, the mixture is stirred at $-78^\circ C$ for 1 hour, and a solution of 15.9 g (80 mmol) of *N*,4-dimethoxy-*N*-methylbenzamide in 20 mL of THF is added dropwise. The reaction medium is stirred at $-78^\circ C$ for 1 hour and the
25 bath of cardice/acetone is then removed and the reaction medium is stirred, while allowing the temperature to return gradually to room temperature,

for 18 hours. The mixture is hydrolysed with 100 mL of water, basified to pH = 12 with 2N NaOH solution and then extracted with tert-butyl methyl ether. The aqueous phase containing the carboxylate is acidified
5 with 5N HCl solution to pH 1 and extracted with dichloromethane. The dichloromethane phase is washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated. The product is crystallized from isopropyl ether; after filtering and drying,
10 14.6 g of white crystals are obtained (yield = 64%).
m.p. = 170°C (Mettler FP62)
LC/MS: MH^+ = 287 (Rt = 7.07 minutes)
 1H NMR δ in ppm (DMSO d 6): 3.85 (s, 3H); 3.90 (s, 3H);
7.03 (d, J = 8.5 Hz, 2H); 7.24 (dd, J_1 = 8.5 Hz, J_2 =
15 2.5 Hz, 1H); 7.35 (d, J = 8.5 Hz, 1H); 7.42 (d, J = 2.5 Hz, 1H); 7.61 (d, J = 8.5 Hz, 2H); 13.1 (s, 1H, COOH).

3.3. 7-Methoxy-4-(4-methoxyphenyl)-2H-phthalazin-1-one

18.5 mL (380 mmol) of hydrazine hydrate are added to a
20 solution of 21.6 g (75 mmol) of 5-methoxy-2-(4-methoxybenzoyl)benzoic acid in 150 mL of ethanol and the mixture is refluxed for 2 hours. The reaction medium is cooled and then filtered. The precipitate obtained is washed with ethanol and then dried under
25 reduced pressure at 40°C. 19 g of a white solid are obtained (90% yield).

m.p. = 245°C (Mettler FP62)

LC/MS: MH^+ = 283 (Rt = 6.98 minutes)

1H NMR δ in ppm (DMSO d 6): 3.86 (s, 3H); 3.98 (s, 3H);
7.12 (d, J = 8.5 Hz, 2H); 7.48 (dd, J_1 = 9 Hz, J_2 = 2.7
5 Hz, 1H); 7.52 (d, J = 8.5 Hz, 2H); 7.67 (d, J = 9.0 Hz,
1H); 7.75 (d, J = 2.7 Hz, 1H); 12.72 (s, 1H, NH).

3.4. 1-Chloro-7-methoxy-4-(4-methoxyphenyl)phthalazine

19 g (67 mmol) of 7-methoxy-4-(4-methoxyphenyl)-2H-
10 phthalazin-1-one are dissolved in 100 mL of phosphoryl
chloride. The solution is heated at 80°C for 2 hours.
The reaction medium is cooled to room temperature and
then poured slowly into 500 mL of water at 40-50°C with
stirring. The mixture is then stirred at 5°C, basified
15 by addition of 35% sodium hydroxide solution and then
extracted with dichloromethane. The organic phase is
washed with water and then with brine and dried over
anhydrous sodium sulfate. After filtration and
evaporation under reduced pressure, 19.3 g of a beige-
20 coloured powder are obtained (yield = 96%).

m.p. = 173°C

LC/MS: MH^+ = 301 (Rt = 8.52 minutes)

1H NMR δ in ppm (DMSO d 6): 3.90 (s, 3H); 4.07 (s, 3H);
7.19 (d, J = 8.5 Hz, 2H); 7.60 (d, J = 2.5 Hz, 1H);
25 7.68 (d, J = 8.5 Hz, 2H); 7.72 (dd, J_1 = 9.2 Hz, J_2 = 2.5
Hz, 1H); 8.02 (d, J = 9.2 Hz, 1H).

3.5. 1-(1-Benzylpiperidin-4-yl)-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine

10.1 g (53 mmol) of (4-amino-1-benzyl)piperidine and 1.44 g (27 mmol) of ammonium chloride are added to a
5 suspension of 8 g (26.6 mmol) of 1-chloro-7-methoxy-4-(4-methoxyphenyl)phthalazine in 50 mL of 1-butanol. The mixture is refluxed (oil bath at 140°C) for 7 hours. The reaction medium is cooled to room temperature, hydrolysed with 50 mL of saturated aqueous sodium
10 hydrogen carbonate solution and then extracted with ethyl acetate. The organic phase is washed with brine, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The residue obtained is purified by chromatography on a column of silica gel
15 (solvent: 95/5 (v/v) dichloromethane/methanol). The yellow oil thus obtained forms a solid by trituration in isopropyl ether. After filtering and drying, 10.5 g of white powder are obtained (yield = 87%).
m.p. = 150°C (Mettler FP62)
20 LC/MS: MH^+ = 455 (Rt = 4.71 minutes)
 1H NMR δ in ppm (DMSO d 6): 1.7-1.8 (m, 2H); 2.0-2.2 (m, 4H); 2.90-3.0 (m, 2H); 3.54 (s, 2H); 3.86 (s, 3H); 4.0 (s, 3H); 4.2-4.3 (m, 1H); 7.0 (d, J = 7.5 Hz; 1H, NH); 7.10 (d, J = 8.5 Hz, 2H); 7.25-7.40 (m, 5H); 7.43 (dd;
25 J₁ = 9.0 Hz; J₂ = 2.5 Hz, 1H); 7.53 (d, J = 8.5 Hz, 2H); 7.75-7.77 (m, 2H).

Example 4: (compound 4)

7-Methoxy-4-(4-methoxyphenyl)-N-[8-(naphthalen-2-ylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]phthalazin-1-amine

5 **4.1. N-[8-(naphthalen-2-ylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]acetamide**

1.6 g (9.5 mmol) of N-[8-azabicyclo[3.2.1]oct-3-yl]acetamide prepared according to Dostert et al. (European Journal of Medicinal Chemistry 1984, 19 (2), 105-110) are dissolved in 45 mL of acetone, and 5.2 g of potassium carbonate and 2.5 g (11.4 mmol) of 2-(bromomethyl)naphthalene are added. The mixture is refluxed with stirring for 18 hours. After cooling, the acetone is partially evaporated off. Water is added to 15 the residue, and the mixture is extracted with dichloromethane. The organic phase is extracted with 1N hydrochloric acid. The acidic aqueous phase obtained is basified with 1N sodium hydroxide and then extracted with dichloromethane. The extract is washed with water 20 and with brine, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The residue obtained is filtered on silica gel (solvent: 95/5 (v/v) dichloromethane/methanol). 2.2 g of a pasty oil are obtained (84% yield).

25 LC/MS: MH^+ = 309 (R_t = 4.49 minutes)

1H NMR δ in ppm (DMSO d_6): 1.5-1.65 (m, 6H); 1.77 (s, 3H); 2.0-2.1 (m, 2H); 3.1-3.2 (m, 2H); 3.70 (s, 2H);

3.9-4.0 (m, 1H); 7.4-7.6 (m, 3H); 7.7 (d, $J = 8.2$ Hz, 1H, NH); 7.82-7.95 (m, 4H).

4.2. N-[8-(naphthalen-2-ylmethyl)-8-

5 azabicyclo[3.2.1]oct-3-yl]amine

4 g (12.9 mmol) of N-[8-(naphthalen-2-ylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]acetamide are poured into 13 mL of 5N hydrochloric acid. The mixture is refluxed for 4 hours and then cooled in an ice bath, basified
10 with 35% sodium hydroxide and extracted three times with ethyl acetate. The combined extracts are washed with water and with brine, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. 3.2 g of oily product are obtained (94% yield).

15 LC/MS: $MH^+ = 267$ (Rt = 1.71 minutes)

1H NMR δ in ppm (DMSO d_6): 1.3-1.45 (m, 2H); 1.5-1.65 (m, 6H); 1.9-2.05 (m, 2H); 2.8 (m, 1H, CH axial); 3.1-3.2 (m, 2H); 3.65 (s, 2H); 7.4-7.6 (m, 3H); 7.75-7.9 (m, 4H).

20

4.3. 7-Methoxy-4-(4-methoxyphenyl)-N-[8-(naphthalen-2-ylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]phthalazin-1-amine

This compound is obtained according to the procedure
25 described in 1.4. by reacting N-[8-(naphthalen-2-ylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]amine and 1-chloro-7-methoxy-4-(4-methoxyphenyl)phthalazine.

Example 5: (compound 8)**N-(1-benzylpiperidin-4-yl)-7-methoxy-4-(thiophen-2-yl)phthalazin-1-amine****5.1. 5-Methoxy-2-(thiophene-2-carbonyl)benzoic acid**

This compound is obtained according to the procedure described in 1.1. by reacting thiophene-2-carboxylic acid chloride and 2-bromo-5-methoxybenzoic acid after halogen-lithium exchange. It is used in crude form in the following reaction.

5.2. 7-Methoxy-4-(thiophen-2-yl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-(thiophene-2-carbonyl)benzoic acid with hydrazine hydrate.

LC/MS: MH^+ = 259 (Rt = 7.50 minutes)

5.3. 1-Chloro-7-methoxy-4-(thiophen-2-yl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(thiophen-2-yl)-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 199°C (Mettler FP62)

LC/MS: MH^+ = 277 (Rt = 7.99 minutes)

1H NMR δ in ppm (DMSO d 6): 4.07 (s, 3H); 7.34-7.38 (m, 1H); 7.60 (d, J = 2.7 Hz, 1H); 7.78 (dd, J_1 = 9.2 Hz, J_2

= 2.7 Hz, 1H); 7.86 (d, J = 3.7 Hz, 1H); 7.95 (d, J = 5.2 Hz, 1H); 8.50 (d, J = 9.2 Hz, 1H).

5.4. N-(1-benzylpiperidin-4-yl)-7-methoxy-4-(thiophen-2-yl)phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(thiophen-2-yl)phthalazine with 4-amino-1-benzylpiperidine.

10

Example 6: (compound 16)

N-(1-benzylpiperidin-4-yl)-7-methoxy-4-(5-methylthiophen-2-yl)phthalazin-1-amine

15 6.1. 5-methoxy-2-(5-methylthiophene-2-carbonyl)benzoic acid

This compound is obtained according to the procedure described in 1.1. by reacting 5-methylthiophen-2-yl chloride and 2-bromo-5-methoxybenzoic acid after
20 halogen-lithium exchange. It is used in crude form in the following reaction.

6.2. 7-Methoxy-4-(5-methylthiophen-2-yl)-2H-phthalazin-1-one

25 This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-

(5-methylthiophene-2-carbonyl)benzoic acid with hydrazine hydrate.

LC/MS: MH^+ = 273 (R_t = 7.58 minutes)

5 **6.3. 1-Chloro-7-methoxy-4-(5-methylthiophen-2-yl)phthalazine**

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(5-methylthiophen-2-yl)-2H-phthalazin-1-one with
10 phosphoryl chloride.

LC/MS: MH^+ = 291 (R_t = 8.74 minutes)

1H NMR δ in ppm (DMSO d_6): 2.59 (s, 3H); 4.08 (s, 3H);
7.06 (m, 1H); 7.60 (d, J = 2.7 Hz, 1H); 7.68 (d, J =
3.5 Hz, 1H); 7.77 (dd, J_1 = 9.2 Hz, J_2 = 2.7 Hz, 1H);
15 8.51 (d, J = 9.2 Hz, 1H).

6.4. N-(1-benzylpiperidin-4-yl)-7-methoxy-4-(5-methylthiophen-2-yl)phthalazin-1-amine

This compound is obtained according to the procedure
20 described in 1.4. by reacting 1-chloro-7-methoxy-4-(5-methylthiophen-2-yl)phthalazine with 4-amino-1-benzylpiperidine.

Example 7: (compound 6)

25 **N-(1-benzylpiperidin-4-yl)-7-methoxy-4-(3-methoxyphenyl)phthalazin-1-amine**

7.1 5-methoxy-2-(3-methoxybenzoyl)benzoic acid

This compound is obtained according to the procedure described in 1.1. by reacting 3-methoxybenzoyl chloride and 2-bromo-5-methoxybenzoic acid after halogen-lithium
5 exchange. It is used in crude form in the following reaction.

7.2. 7-Methoxy-4-(3-methoxyphenyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure
10 described in 1.2. by reacting unpurified 5-methoxy-2-(3-methoxybenzoyl)benzoic acid with hydrazine hydrate.
m.p. = 219°C (Mettler FP62)

LC/MS: MH^+ = 283 (Rt = 7.41 minutes)

1H NMR δ in ppm (DMSO d_6): 3.83 (s, 3H); 3.97 (s, 3H);
15 7,10 - 7.16 (m, 3H); 7.44 - 7.51 (m, 2H); 7.67 (d, J = 9Hz, 1H); 7.75 (d, J = 2.5 Hz, 1H); 12.80 (s, 1H, NH).

7.3. 1-Chloro-7-methoxy-4-(3-methoxyphenyl)-phthalazine

20 This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(3-methoxyphenyl)-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 98°C (Mettler FP62)

25 LC/MS: MH^+ = 301 (Rt = 8.07 minutes)

1H NMR δ in ppm (DMSO d_6): 3.86 (s, 3H); 4.08 (s, 3H);
7.18-7.27 (m, 3H); 7.52-7.58 (m, 1H); 7.62 (d, J = 2.5

Hz, 1H); 7.72 (dd, $J_1 = 9.2$ Hz, $J_2 = 2.5$ Hz, 1H); 8.02 (d, $J = 9.2$ Hz, 1H).

7.4. 1-(1-Benzylpiperidin-4-yl)-7-methoxy-4-(3-methoxyphenyl)phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(3-methoxyphenyl)phthalazine with 4-amino-1-benzylpiperidine.

10

Example 8: (compound 3)

7-methoxy-4-(4-methoxyphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(4-methoxyphenyl)phthalazine described in 3.4 with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

15

Example 9: (compound 5)

7-methoxy-4-(3-methoxyphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(3-methoxyphenyl)phthalazine described in 7.3 with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

20

25

Example 10: (compound 2)

7-methoxy-4-(2-methoxyphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

5 **10.1. 5-methoxy-2-(2-methoxybenzoyl)benzoic acid**

This compound is obtained according to the procedure described in 1.1. by reacting 2-methoxybenzoyl chloride and 2-bromo-5-methoxybenzoic acid after halogen-lithium exchange. It is used in crude form in the following
10 reaction.

10.2. 7-Methoxy-4-(2-methoxyphenyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-
15 (2-methoxybenzoyl)benzoic acid with hydrazine hydrate.

m.p. = 275°C (Mettler FP62)

LC/MS: MH^+ = 283 (Rt = 7.76 minutes)

¹H NMR δ in ppm (DMSO d 6): 3.70 (s, 3H); 3.96 (s, 3H);
7.11-7.15 (m, 1H); 7.20-7.23 (d, J = 8.7 Hz, 2H); 7.32-
20 7.35 (m, 1H); 7.39-7.44 (m, 1H); 7.50-7.55 (m, 1H);
7.69 (d, J = 2.7 Hz, 1H); 12.70 (s, 1H, NH)

10.3. 1-Chloro-7-methoxy-4-(2-methoxyphenyl)-phthalazine

25 This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(2-

methoxyphenyl)-2*H*-phthalazin-1-one with phosphoryl chloride.

m.p. = 157°C (Mettler FP62)

LC/MS: MH^+ = 301 (Rt = 7.81 minutes)

5 1H NMR δ in ppm (DMSO *d* 6): 3.69 (s, 3H); 4.06 (s, 3H); 7.15-7.22 (m, 1H); 7.28 (d, *J* = 7.6 Hz, 1H); 7.42 (dd, *J*₁ = 7.6 Hz, *J*₂ = 1.7 Hz, 1H); 7.55-7.68 (m, 4H).

10.4. 7-methoxy-4-(2-methoxyphenyl)-*N*-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(2-methoxyphenyl)phthalazine described with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

15

Example 11: (compound 10)

4-(3,4-Dimethoxyphenyl)-7-methoxy-*N*-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

20 11.1 2-(3,4-dimethoxybenzoyl)-5-methoxybenzoic acid

This compound is obtained according to the procedure described in 1.1. by reacting 3,4-dimethoxybenzoyl chloride and 2-bromo-5-methoxybenzoic acid after halogen-lithium exchange. It is used in crude form in
25 the following reaction.

11.2. 4-(3,4-Dimethoxyphenyl)-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-(3,4-dimethoxybenzoyl)-5-methoxybenzoic acid with hydrazine hydrate.

m.p. = 258°C (Mettler FP62)

LC/MS: MH^+ = 313 (Rt = 6.54 minutes)

1H NMR δ in ppm (DMSO d 6): 3.81 (s, 3H); 3.86 (s, 3H); 3.97 (s, 3H); 7.12-7.16 (m, 3H); 7.48 (dd, J_1 = 9Hz, J_2 = 2.7 Hz, 1H) 7.71-7.76 (m, 2H); 12.71 (s, 1H, NH).

11.3. 1-Chloro-4-(3,4-dimethoxyphenyl)-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(3,4-dimethoxyphenyl)-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 190°C (Mettler FP62)

LC/MS: MH^+ = 331 (Rt = 7.43 minutes)

1H NMR δ in ppm (DMSO d 6): 3.85 (s, 3H); 3.89 (s, 3H); 4.08 (s, 3H); 7.18-7.32 (m, 3H); 7.61 (d, J = 2.5 Hz, 1H); 7.72 (dd, J_1 = 9.2 Hz, J_2 = 2.5 Hz, 1H); 8.01 (d, J = 9.2 Hz, 1H).

11.4. 4-(3,4-Dimethoxyphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(3,4-dimethoxyphenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

5

Example 12: (compound 15)

5,7-dimethoxy-4-(4-methoxyphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

10

This compound is obtained according to the procedure described in 2.4 by reacting 4-chloro-6,8-dimethoxy-1-(4-methoxyphenyl)phthalazine described in 2.3 with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

15 On treatment with hydrochloric ether, a precipitate forms, which is filtered off, washed with ethyl ether and dried under reduced pressure. The hydrochloride obtained is in the form of a white solid.

20 **Example 13: (compound 13)**

N-(1-benzylpiperidin-4-yl)-5,7-dimethoxyphthalazin-1-amine

13.1. 5,7-Dimethoxy-2H-phthalazin-1-one

3 g (13.4 mmol) of methyl 2-formyl-3,5-dimethoxybenzoate are dissolved in 80 mL of methanol and 10 mL of 2N sodium hydroxide solution. The mixture
25 is stirred for 18 hours at room temperature. The

methanol is evaporated off under reduced pressure and the concentrate is acidified with 2N hydrochloric acid. The precipitate formed is filtered off and then dried. 2.7 g of acid in the form of a yellow solid are
5 obtained.

The 2-formyl-3,5-dimethoxybenzoic acid (2.7 g, 13 mmol) is partially dissolved in 300 mL of ethanol, and 6.2 mL of hydrazine hydrate are then added. The mixture is refluxed for 6 hours. After cooling, the precipitate
10 formed is filtered off and then dried. 2.3 g of a white solid are obtained (86% yield).

LC/MS: MH^+ = 207 (Rt = 5.35 minutes)

1H NMR δ in ppm (DMSO d 6): 3.95 (s, 3H); 3.98 (s, 3H);
7.02 (d, J = 2.5 Hz, 1H); 7.21 (d, J = 2.5 Hz, 1H);
15 8.30 (s, 1H); 12.61 (s, 1H, NH)

13.2. 1-Chloro-5,7-dimethoxyphthalazine

1 g (4.9 mmol) of 5,7-dimethoxy-2H-phthalazin-1-one and 10mL of phosphoryl chloride are heated at 80°C for 2
20 hours. After cooling to room temperature, the reaction medium is poured dropwise into 50 mL of water and the mixture is then basified with 6N sodium hydroxide solution and extracted with dichloromethane. The organic phase is washed with water and with brine,
25 dried over anhydrous sodium sulfate and then evaporated under reduced pressure. 1 g of a beige-coloured solid is obtained (91% yield).

m.p. = 167°C (Mettler FP62)

LC/MS: MH^+ = 225 (Rt = 6.15 minutes)

1H NMR δ in ppm (DMSO d 6): 4.03 (s, 3H); 4.06 (s, 3H);

7.04 (d, J = 2.2 Hz, 1H); 7.15 (d, J = 2.2 Hz, 1H);

5 9.49 (s, 1H).

13.3. N-(1-benzylpiperidin-4-yl)-5,7-

dimethoxyphthalazin-1-amine

This compound is obtained according to the procedure
10 described in 2.4 by reacting 1-chloro-5,7-
dimethoxyphthalazine with 4-amino-1-benzylpiperidine.

Example 14: (compound 14)

15 5,7-dimethoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4- yl]phthalazin-1-amine

This compound is obtained according to the procedure
described in 2.4 by reacting 1-chloro-5,7-
dimethoxyphthalazine described in 13.2 with 4-amino-1-
(naphthalen-2-ylmethyl)piperidine.

20

Example 15: (compound 9)

4-(4-methoxyphenyl)-7-methyl-N-[1-(naphthalen-2- ylmethyl)piperidin-4-yl]phthalazin-1-amine

25 15.1 2-(4-methoxybenzoyl)-5-methylbenzoic acid

This compound is obtained according to the procedure
described in 1.1. by reacting 4-methoxybenzoyl chloride

and 2-bromo-5-methylbenzoic acid after halogen-lithium exchange. It is used in crude form in the following reaction.

5 **15.2. 4-(4-Methoxyphenyl)-7-methyl-2H-phthalazin-1-one**

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-(4-methoxybenzoyl)-5-methylbenzoic acid with hydrazine hydrate.

10 LC/MS: MH^+ = 267 (Rt = 7.29 minutes)

1H NMR δ in ppm (DMSO d 6): 2.55 (s, 3H); 3.86 (s, 3H); 7.12 (d, J = 8.5 Hz, 2H); 7.53 (d, J = 8.5 Hz, 2H); 7.62 (d, J = 8.2 Hz, 1H); 7.74 (dd, J_1 = 8.2 Hz, J_2 = 2 Hz, 1H); 8.16 (d, J = 2 Hz, 1H); 12.7 (s, 1H, NH).

15

15.3. 1-Chloro-4-(4-methoxyphenyl)-7-methylphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(4-methoxyphenyl)-7-methyl-2H-phthalazin-1-one with phosphoryl chloride.

20 m.p. = 154°C (Mettler FP62)

LC/MS: MH^+ = 285 (Rt = 8.36 minutes)

1H NMR δ in ppm (DMSO d 6): 2.67 (s, 3H); 3.90 (s, 3H); 7.20 (d, J = 8.5 Hz, 2H); 7.70 (d, J = 8.5 Hz, 2H); 7.95-7.99 (m, 2H); 8.18 (m, 1H).

25

15.4. 4-(4-methoxyphenyl)-7-methyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(4-methoxyphenyl)-7-methylphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

5

Example 16: (compound 20)

4-Ethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

10 **16.1. 5-methoxy-2-propionylbenzoic acid**

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with N-methoxy-N-methylpropionamide. It is used in crude form in the following reaction.

15

16.2. 4-Ethyl-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-propionylbenzoic acid with hydrazine hydrate.

20

LC/MS: MH^+ = 205 (R_t = 6.32 minutes)

1H NMR δ in ppm (DMSO d 6): 1.25 (t, J = 7.5 Hz, 3H);

2.92 (q, J = 7.5 Hz, 2H); 3.94 (s, 3H); 7.50 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.60 (d, J = 2.7 Hz, 1H); 7.94 (d,

25 J = 9 Hz, 1H); 12.38 (s, 1H, NH).

16.3. 1-Chloro-4-ethyl-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-ethyl-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 191°C (Mettler FP62)

5 LC/MS: MH^+ = 223 (Rt = 6.84 minutes)

1H NMR δ in ppm (DMSO d 6): 1.36 (t, J = 7.5 Hz, 3H); 3.30 (q, J = 7.5 Hz, 2H); 4.04 (s, 3H); 7.50 (d, J = 2.7 Hz, 1H); 7.71 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 8.30 (d, J = 9 Hz, 1H).

10

16.4. 4-Ethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-ethyl-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

15

Example 17: (compound 21)

4-Benzyl-7-methoxy-N-[1-(naphthalen-2-

20 **ylmethyl)piperidin-4-yl]phthalazin-1-amine**

17.1. 5-methoxy-2-(phenylacetyl)benzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with phenyl-N-methoxy-N-acetamide. It is used in crude form in the following reaction.

25

17.2. 4-Benzyl-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-(phenylacetyl)benzoic acid with hydrazine hydrate.

LC/MS: MH^+ = 267 (Rt = 6.50 minutes)

1H NMR δ in ppm (DMSO d 6): 3.92 (s, 3H); 4.27 (s, 2H); 7.15-7.33 (m, 5H); 7.44 (dd, J_1 = 8.8 Hz, J_2 = 2.7 Hz, 1H); 7.66 (d, J = 2.7 Hz, 1H); 7.90 (d, J = 8.8 Hz, 1H); 12.52 (s, 1H, NH).

17.3. 4-Benzyl-1-chloro-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-benzyl-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

LC/MS: MH^+ = 285 (Rt = 7.34 minutes)

1H NMR δ in ppm (DMSO d 6): 4.02 (s, 3H); 4.68 (s, 2H); 7.17-7.35 (m, 5H); 7.52 (d, J = 2.5 Hz, 1H); 7.69 (dd, J_1 = 9.2 Hz, J_2 = 2.5 Hz, 1H); 8.31 (d, J = 9.2 Hz, 1H).

17.4. 4-Benzyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 4-benzyl-1-chloro-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 18: (compound 22)

4-Benzyl-5,7-dimethoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

5 **17.1. 3,5-dimethoxy-2-(phenylacetyl)benzoic acid**

This compound is synthesized by reacting methyl 3,5-dimethoxybenzoate with phenylacetyl chloride via the Friedel-Crafts reaction, followed by saponification of the ester obtained, according to the method described
10 in 2.1. It is used in crude form in the following reaction.

18.2. 4-Benzyl-5,7-dimethoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure
15 described in 1.2. by reacting unpurified 3,5-dimethoxy-2-(phenylacetyl)benzoic acid with hydrazine hydrate.

LC/MS: MH^+ = 297 (Rt = 7.98 minutes)

1H NMR δ in ppm (DMSO d 6): 3.75 (s, 3H); 3.90 (s, 3H);
4.30 (s, 2H); 6.89 (d, J = 2.4 Hz, 1H); 7.12-7.16 (m,
20 3H); 7.20-7.30 (m, 3H); 12.51 (s, 1H, NH).

18.3. 4-Benzyl-1-chloro-5,7-dimethoxyphthalazine

This compound is obtained according to the procedure
described in 1.3. by reacting 4-benzyl-5,7-dimethoxy-
25 2H-phthalazin-1-one with phosphoryl chloride.

1H NMR δ in ppm (DMSO d 6): 3.88 (s, 3H); 4.0 (s, 3H);
4.71 (s, 2H); 7.03-7.28 (m, 7H).

18.4. 4-Benzyl-5,7-dimethoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure
5 described in 1.4. by reacting 4-benzyl-1-chloro-5,7-dimethoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 19: (compound 23)

10 **5,7-Dimethoxy-4-ethyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine**

19.1. 3,5-dimethoxy-2-propionylbenzoic acid

This compound is synthesized by reacting methyl 3,5-dimethoxybenzoate with propionyl chloride via the
15 Friedel-Crafts reaction, followed by saponification of the ester obtained, according to the method described in 2.1. It is used in crude form in the following reaction.

20

19.2. 5,7-Dimethoxy-4-ethyl-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 3,5-dimethoxy-2-propionylbenzoic acid with hydrazine hydrate.

25 ^1H NMR δ in ppm (DMSO d 6): 1.15 (t, J = 7.2 Hz, 3H); 2.99 (q, J = 7.2 Hz, 2H); 3.92 (s, 3H); 3.94 (s, 3H);

6.99 (d, $J = 2.7$ Hz, 1H); 7.3 (d, $J = 2.7$ Hz, 1H);
12.35 (s, 1H, NH).

19.3. 1-Chloro-5,7-dimethoxy-4-ethylphthalazine

5 This compound is obtained according to the procedure described in 1.3. by reacting 5,7-dimethoxy-4-ethyl-2H-phthalazin-1-one with phosphoryl chloride.

^1H NMR δ in ppm (DMSO d_6): 1.26 (t, $J = 7.2$ Hz, 3H);
3.34 (q, $J = 7.2$ Hz, 2H); 4.0 (s, 3H); 4.03 (s, 3H);
10 7.12 (d, $J = 2.4$ Hz, 1H); 7.15 (d, $J = 2.4$ Hz, 1H).

19.4. 5,7-dimethoxy-4-ethyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure
15 described in 1.4. by reacting 1-chloro-5,7-dimethoxy-4-ethylphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 20: (compound 24)

20 7-methoxy-4-methoxymethyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine
hydrochloride

20.1. 5-methoxy-2-(methoxyacetyl)benzoic acid

25 This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with *n*-butyllithium with 2,N-dimethoxy-

N-methylacetamide. It is used in crude form in the following reaction.

20.2. 7-Methoxy-4-methoxymethyl-2H-phthalazin-1-one

- 5 This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-(methoxyacetyl)benzoic acid with hydrazine hydrate.

m.p. = 184°C (Mettler FP62)

LC/MS: MH^+ = 221 (Rt = 5.33 minutes)

- 10 1H NMR δ in ppm (DMSO d 6): 3.33 (s, 3H); 3.96 (s, 3H); 4.62 (s, 2H); 7.53 (dd, J_1 = 8.8 Hz, J_2 = 2.7 Hz, 1H); 7.66 (d, J = 2.7 Hz, 1H); 8.0 (d, J = 8.8 Hz, 1H); 12.61 (s, 1H, NH).

15 **20.3. 1-Chloro-7-methoxy-4-methoxymethylphthalazine**

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-methoxymethyl-2H-phthalazin-1-one with phosphoryl chloride.

- 20 1H NMR δ in ppm (DMSO d 6): 3.33 (s, 3H); 4.06 (s, 3H); 5.02 (s, 2H); 7.56 (d, J = 2.7 Hz, 1H); 7.77 (dd, J_1 = 9.2 Hz, J_2 = 2.7 Hz, 1H); 8.35 (d, J = 9.2 Hz, 1H).

- 20.4. 7-methoxy-4-methoxymethyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine hydrochloride**
- 25

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-methoxymethylphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The hydrochloride is obtained
 5 after treatment with a solution of hydrogen chloride in isopropanol.

Example 21: (compound 33)

4-Cyclopropyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine
 10

21.1. 2-cyclopropanecarbonyl-5-methoxybenzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic
 15 acid pretreated with n-butyllithium with cyclopropyl-N-methoxy-N-methylcarboxamide. A yellow powder is obtained by precipitation in isopropyl ether.

m.p. = 117°C (Mettler FP62)

¹H NMR δ in ppm (DMSO d 6): 0.97-1.07 (m, 4H); 2.35-2.50
 20 (m, 1H); 3.87(s, 3H); 7.15-7.20 (m, 2H); 7.71 (dd, J₁ = 8.8 Hz, J₂ = 2.5 Hz, 1H) (COOH signal not visible).

21.2. 4-Cyclopropyl-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 2-cyclopropanecarbonyl-5-methoxybenzoic acid with hydrazine hydrate.

m.p. = 189°C (Mettler FP62)

- 5 ^1H NMR δ in ppm (DMSO d 6): 0.85-1.02 (m, 4H); 2.38-2.45 (m, 1H); 3.96 (s, 3H); 7.53 (dd, $J_1 = 9$ Hz, $J_2 = 2.7$ Hz, 1H); 7.66 (d, $J = 2.7$ Hz, 1H); 8.22 (d, $J = 9$ Hz, 1H); 12.31 (s, 1H, NH).

10 **21.3. 1-Chloro-4-cyclopropyl-7-methoxyphthalazine**

This compound is obtained according to the procedure described in 1.3. by reacting 4-cyclopropyl-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

LC/MS: $\text{MH}^+ = 235$ ($R_t = 7.67$ minutes)

- 15 ^1H NMR δ in ppm (DMSO d 6): 1.13-1.26 (m, 4H); 2.80-2.95 (m, 1H); 4.05 (s, 3H); 7.51 (d, $J = 2.5$ Hz, 1H); 7.76 (dd, $J_1 = 9.2$ Hz, $J_2 = 2.5$ Hz, 1H); 8.57 (d, $J = 9$ Hz, 1H).

20 **21.4. 4-Cyclopropyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine**

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-cyclopropyl-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-

- 25 ylmethyl)piperidine.

Example 22: (compound 42)

**4-(1,3-Benzodioxol-5-yl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine
dihydrochloride**

5

22.1. 2-(1,3-Benzodioxol-5-yl)carbonyl-5-methoxybenzoic acid

This compound is obtained according to the procedure described in 1.1. by reacting 1,3-benzodioxole-5-
10 carboxylic acid and 2-bromo-5-methoxybenzoic acid after halogen-lithium exchange. It is used in crude form in the following reaction.

**22.2. 4-(1,3-Benzodioxol-5-yl)-7-methoxy-2H-phthalazin-
15 1-one**

This compound is obtained according to the procedure described in 1.2. by reacting 2-(1,3-benzodioxol-5-yl)carbonyl-5-methoxybenzoic acid unpurified with hydrazine hydrate.

20 m.p. = 271°C (Mettler FP62)

LC/MS: MH^+ = 297 (Rt = 6.83 minutes)

1H NMR δ in ppm (DMSO d 6): 3.95 (s, 3H); 6.12 (s, 2H);
7.01-7.12 (m, 3H); 7.46 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.66 (d, J = 9 Hz, 1H); 7.71 (d, J = 2.7 Hz, 1H);
25 12.69 (s, 1H, NH).

22.3. 4-(1,3-Benzodioxol-5-yl)-1-chloro-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(1,3-benzodioxol-5-yl)-
 5 7-methoxy-2*H*-phthalazin-1-one with phosphoryl chloride.
 m.p. = 178°C (Mettler FP62)

LC/MS: MH^+ = 315 (Rt = 7.81 minutes)

1H NMR δ in ppm (DMSO *d* 6): 4.05 (s, 3H); 6.17 (s, 2H);
 7.12-7.20 (m, 2H); 7.27 (d, J = 1.5 Hz, 1H); 7.58 (d,
 10 J = 2.7 Hz, 1H); 7.70 (dd, J_1 = 9.3 Hz, J_2 = 2.7 Hz,
 1H); 8.01 (d, J = 9.3 Hz, 1H).

**22.4. 4-(1,3-Benzodioxol-5-yl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-
 15 amine dihydrochloride**

This compound is obtained according to the procedure described in 1.4. by reacting 4-(1,3-benzodioxol-5-yl)-
 1-chloro-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. By treatment with a
 20 solution of hydrogen chloride in diethyl ether, a precipitate forms, which is filtered off, washed with diethyl ether and dried under reduced pressure. The hydrochloride obtained is in the form of a white solid.

25 Example 23: (compound 43)

4-(4-Chlorophenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

23.1. 2-(4-chlorobenzoyl)-5-methoxybenzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 4-chloro-N-methoxy-N-methylbenzamide. It is used in crude form in the following reaction.

23.2. 4-(4-Chlorophenyl)-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 2-(4-chlorobenzoyl)-5-methoxybenzoic acid unpurified with hydrazine hydrate.

m.p. = 274°C (Mettler FP62)

LC/MS: MH^+ = 287 (Rt = 7.20 minutes)

1H NMR δ in ppm (DMSO d 6): 3.97 (s, 3H); 7.48 (dd, J_1 = 8.5 Hz, J_2 = 2.5 Hz, 1H); 7.61-7.65 (m, 5H); 7.74 (d, J = 2.5 Hz, 1H); 12.82 (s, 1H, NH).

23.3. 1-Chloro-4-(4-chlorophenyl)-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(4-chlorophenyl)-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 199°C (Mettler FP62)

LC/MS: MH^+ = 305 (Rt = 8.05 minutes)

1H NMR δ in ppm (DMSO d 6): 4.07 (s, 3H); 7.62 (d, J = 2.5 Hz, 1H); 7.67-7.77 (m, 5H); 7.96 (d, J = 9 Hz, 1H).

23.4. 4-(4-Chlorophenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(4-chlorophenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 24: (compound 45)

7-Methoxy-4)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-(4-trifluoromethyl-phenylphthalazin-1-amine

24.1. 5-methoxy-2-(4-trifluoromethylbenzoyl)benzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with N-methoxy-N-methyl-4-trifluoromethylbenzamide. It is used in crude form in the following reaction.

24.2. 7-Methoxy-4-(4-trifluoromethylphenyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 5-methoxy-2-(4-trifluoromethylbenzoyl)benzoic acid unpurified with hydrazine hydrate.

m.p. = 264°C (Köfler)

LC/MS: MH⁺ = 321 (Rt = 8.14 minutes)

^1H NMR δ in ppm (DMSO d_6): 3.96 (s, 3H); 7.46 (dd, $J_1 = 9$ Hz, $J_2 = 2.7$ Hz, 1H); 7.62 (d, $J = 9$ Hz, 1H); 7.74 (d, $J = 2.7$ Hz, 1H); 7.82 (d, $J = 8.2$, 2H); 7.92 (d, $J = 8.2$, 2H); 12.87 (s, 1H, NH).

5

24.3. 1-Chloro-7-methoxy-4-(4-trifluoromethylphenyl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(4-trifluoromethylphenyl)-2H-phthalazin-1-one with phosphoryl chloride.

LC/MS: $\text{MH}^+ = 338$ ($R_t = 8.68$ minutes)

^1H NMR δ in ppm (DMSO d_6): 4.07 (s, 3H); 7.63 (d, $J = 2.5$ Hz, 1H); 7.71 (dd, $J_1 = 9$ Hz, $J_2 = 2.5$ Hz, 1H); 7.91-8.01 (m, 5H).

15

24.4. 7-Methoxy-4)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-(4-trifluoromethylphenyl)phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(4-trifluoromethylphenyl)phthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

20

Example 25: (compound 51)

4-cyclopentyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

5

25.1. 2-cyclopentanecarbonyl-5-methoxybenzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with cyclopentyl-N-methoxy-N-methylcarboxamide. It is used in crude form in the following reaction.

10

25.2. 4-Cyclopentyl-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-cyclopentanecarbonyl-5-methoxybenzoic acid with hydrazine hydrate.

15

m.p. = 232°C (Mettler FP62)

¹H NMR δ in ppm (DMSO d 6): 1.65-1.95 (m, 6H); 1.95-2.10 (m, 2H); 3.55-3.70 (m, 1H); 3.95 (s, 3H); 7.50 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.67 (d, J = 2.7 Hz, 1H); 8.03 (d, J = 9 Hz, 1H); 12.37 (s, 1H, NH).

20

25.3. 1-Chloro-4-cyclopentyl-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-cyclopentyl-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride. The

25

product is too impure for a description by NMR. It is used as obtained in the following amination reaction.

LC/MS: MH^+ = 263 (R_t = 9.04 minutes)

5 **25.4. 4-cyclopentyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride**

This compound is obtained according to the procedure described in 1.4. by reacting impure 1-chloro-4-cyclopentyl-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in isopropanol, followed by crystallization from diisopropyl ether.

15

Example 26: (compound 66)

7-Methoxy-4-(4-methylphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

20 **26.1. 5-methoxy-2-(4-methylbenzoyl)benzoic acid**

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with N-methoxy-N-methyl-4-methylbenzamide. It is used in crude form in the following reaction.

25

26.2. 7-Methoxy-4-(4-methylphenyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-(4-methylbenzoyl)benzoic acid with hydrazine hydrate.

m.p. = 223°C (Mettler FP62)

5 LC/MS: MH^+ = 267 (Rt = 8.07 minutes)

1H NMR δ in ppm (DMSO d 6): 2.40 (s, 3H); 3.95 (s, 3H); 7.35 (d, J = 7.8 Hz, 2H); 7.44-7.48 (m, 3H); 7.63 (d, J = 9 Hz, 1H); 7.72 (d, J = 2.7 Hz, 1H); 12.71 (s, 1H, NH).

10

26.3. 1-Chloro-7-methoxy-4-(4-methylphenyl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(4-methylphenyl)-2H-phthalazin-1-one with phosphoryl

15 chloride.

m.p. = 183°C (Mettler FP62)

LC/MS: MH^+ = 285 (Rt = 7.76 minutes)

1H NMR δ in ppm (DMSO d 6): 2.46 (s, 3H); 4.06 (s, 3H); 7.43 (d, J = 8.5 Hz, 2H); 7.58-7.63 (m, 3H); 7.70 (dd, J₁ = 9 Hz, J₂ = 2.5 Hz, 1H); 7.97 (d, J = 9 Hz, 1H).

20

26.4. 7-Methoxy-4-(4-methylphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(4-methylphenyl)phthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

25

Example 27: (compound 67)

4-Butyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

5

27.1. 5-methoxy-2-pentanoylbenzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with butyl-N-methoxy-N-methylcarboxamide. It is used in crude form in the following reaction.

27.2. 4-Butyl-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-pentanoylbenzoic acid with hydrazine hydrate.

m.p. = 175°C (Mettler FP62)

LC/MS: MH^+ = 233 (Rt = 7.75 minutes)

1H NMR δ in ppm (DMSO d 6): 0.92 (t, J = 7.3 Hz, 3H); 1.32-1.47 (m, 2H); 1.59-1.72 (m, 2H); 2.85-2.92 (m, 2H); 3.94 (s, 3H); 7.49 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.66 (d, J = 2.7 Hz, 1H); 7.93 (d, J = 9 Hz, 1H); 12.37 (s, 1H, NH).

27.3. 4-Butyl-1-chloro-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-butyl-7-methoxy-2*H*-phthalazin-1-one with phosphoryl chloride.

LC/MS: MH^+ = 251 (R_t = 7.10 minutes)

- 5 1H NMR δ in ppm (DMSO d_6): 0.94 (t, J = 7.3 Hz, 3H); 1.35-1.50 (m, 2H); 1.70-1.82 (m, 2H); 3.24-3.32 (m, 2H); 4.04 (s, 3H); 7.51 (d, J = 2.5 Hz, 1H); 7.72 (dd, J_1 = 9 Hz, J_2 = 2.5 Hz, 1H); 8.31 (d, J = 9 Hz, 1H).

10 **27.4. 4-Butyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine**

This compound is obtained according to the procedure described in 1.4. by reacting 4-butyl-1-chloro-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-

15 ylmethyl)piperidine.

Example 28: (compound 71)

4-Cyclopropylmethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

28.1. 2-(2-cyclopropylacetyl)-5-methoxybenzoic acid

- 20 This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with *n*-butyllithium with 2-cyclopropyl-*N*-methoxy-*N*-methylacetamide. It is used in crude form in the following reaction.

25

28.2. 4-Cyclopropylmethyl-7-methoxy-2*H*-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-(2-cyclopropylacetyl)-5-methoxybenzoic acid with hydrazine hydrate.

- 5 ^1H NMR δ in ppm (DMSO d_6): 0.23-0.28 (m, 2H); 0.46-0.52 (m, 2H); 1.09-1.13 (m, 1H); 2.83 (d, $J = 6.7$ Hz, 2H); 3.96 (s, 3H); 7.52 (dd, $J_1 = 8.7$ Hz, $J_2 = 2.7$ Hz, 1H); 7.68 (d, $J = 2.7$ Hz, 1H); 7.99 (d, $J = 8.7$ Hz, 1H); 12.41 (s, 1H, NH).

10

28.3. 1-Chloro-4-cyclopropylmethyl-7-methoxyphthalazine

- This compound is obtained according to the procedure described in 1.3. by reacting 4-cyclopropylmethyl-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.
- 15 LC/MS: $\text{MH}^+ = 249$ ($R_t = 6.91$ minutes)

28.4. 4-Cyclopropylmethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

- 20 This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-cyclopropylmethyl-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

LC/MS: $\text{MH}^+ = 453$ ($R_t = 5.45$ minutes)

- 25 ^1H NMR δ in ppm (DMSO d_6): 0.23-0.26 (m, 2H); 0.43-0.47 (m, 2H); 1.08-1.16 (m, 1H); 1.60-1.80 (m, 2H); 2.03-2.30 (m, 4H); 2.90-3.0 (m, 2H); 2.95 (d, $J = 6.6$ Hz,

2H); 3.74 (s, 2H); 3.96 (s, 3H); 4.15-4.25 (m, 1H);
 6.88 (d, J = 7 Hz, 1H, NH); 7.42-7.58 (m, 4H); 7.73 (d,
 J = 2.5 Hz, 1H); 7.83-7.94 (m, 4H); 8.03 (d, J = 9 Hz,
 1H).

5

Example 29: (compound 82)

4-(4-Fluorophenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

29.1. 2-(4-fluorobenzoyl)-5-methoxybenzoic acid

10 This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 4-fluoro-N-methoxy-N-methylbenzamide. It is used in crude form in the following reaction.

15

29.2. 4-(4-Fluorophenyl)-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-(4-fluorobenzoyl)-5-methoxybenzoic acid with hydrazine
 20 hydrate.

m.p. = 256°C (Mettler FP62)

LC/MS: MH⁺ = 271 (Rt = 6.51 minutes)

¹H NMR δ in ppm (DMSO d 6): 3.97 (s, 3H); 7.35-7.43 (m, 2H), 7.48 (dd, J₁ = 9 Hz, J₂ = 2.7 Hz, 1H); 7.59-7.67
 25 (m, 3H); 7.74 (d, J = 2.7 Hz, 1H); 12.80 (s, 1H, NH).

29.3. 1-Chloro-4-(4-fluorophenyl)-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(4-fluorophenyl)-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

LC/MS: MH^+ = 289 (R_t = 8.58 minutes)

1H NMR δ in ppm (DMSO d_6): 4.06 (s, 3H); 7.42-7.51 (m, 2H), 7.60 (d, J = 2.5 Hz, 1H); 7.69-7.80 (m, 3H); 7.95 (d, J = 9 Hz, 1H).

10

29.4. 4-(4-Fluorophenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(4-fluorophenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 30: (compound 88)

7-Methoxy-4-(4-methoxymethylphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

30.1. 5-methoxy-2-(4-methoxymethylbenzoyl)benzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with N-methoxy-4-methoxymethyl-N-methylbenzamide. The product is crystallized from diisopropyl ether.

25

LC/MS: MH^+ = 301 (R_t = 6.60 minutes)

^1H NMR δ in ppm (DMSO d_6): 3.32 (s, 3H); 3.89 (s, 3H); 4.49 (s, 2H); 7.26 (dd, $J_1 = 8.5$ Hz, $J_2 = 2.5$ Hz, 1H); 7.40-7.45 (m, 4H); 7.63 (d, $J = 8.2$ Hz, 2H); 13.1 (s, 1H, COOH).

5

30.2. 7-Methoxy-4-(4-methoxymethylphenyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 5-methoxy-2-(4-methoxymethylbenzoyl)benzoic acid with hydrazine hydrate.

m.p. = 201°C (Mettler FP62)

LC/MS: $\text{MH}^+ = 297$ ($R_t = 6.54$ minutes)

^1H NMR δ in ppm (DMSO d_6): 3.36 (s, 3H); 3.96 (s, 3H); 4.52 (s, 2H); 7.45-7.58 (m, 5H); 7.64 (d, $J = 9$ Hz, 1H); 7.74 (d, $J = 2.7$ Hz, 1H); 12.78 (s, 1H, NH).

30.3. 1-Chloro-7-methoxy-4-(4-methoxymethylphenyl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(4-methoxymethylphenyl)-2H-phthalazin-1-one with phosphoryl chloride.

LC/MS: $\text{MH}^+ = 315$ ($R_t = 8.26$ minutes)

^1H NMR δ in ppm (DMSO d_6): 3.38 (s, 3H); 4.06 (s, 3H); 4.56 (s, 2H); 7.56 (d, $J = 8.4$ Hz, 2H); 7.62 (d, $J = 2.7$ Hz, 1H); 7.68-7.74 (m, 3H); 7.97 (d, $J = 9$ Hz, 1H).

In this reaction, the predominant product is 1-chloro-4-(4-chloromethylphenyl)-7-methoxyphthalazine.

LC/MS: MH^+ = 319 (Rt = 9.06 minutes) dichloro

5 1H NMR δ in ppm (DMSO d 6): 4.06 (s, 3H); 4.90 (s, 2H); 7.61 (d, J = 2.7 Hz, 1H); 7.71-7.75 (m, 5H); 7.95 (d, J = 9 Hz, 1H).

30.4. 7-Methoxy-4-(4-methoxymethylphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(4-methoxymethylphenyl)phthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 31: (compound 105)

4-[(4-diethylaminomethyl)phenyl]-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine trihydrochloride

31.1. 1-Chloro-4-(4-diethylaminomethylphenyl)-7-methoxyphthalazine

280 mg (2 mmol) of potassium carbonate and 0.3 mL of diethylamine are added to a solution of 319 mg (1 mmol) of 1-chloro-4-(4-chloromethylphenyl)-7-methoxyphthalazine (synthesized in 30.3) in 3 mL of ethanol. The mixture is stirred at 85°C for 4 hours.

The ethanol is evaporated off and the residue is taken up in water and extracted with dichloromethane. The organic extracts are washed with brine, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The residue obtained is purified by chromatography on a column of silica gel (solvent: 95/5 to 85/15 (v/v) dichloromethane/methanol). 287 mg of product are obtained (80% yield).

LC/MS: MH^+ = 356 (R_t = 5.38 minutes)

10

31.2. 4-(4-diethylaminomethylphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine trihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(4-diethylaminomethylphenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The trihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether, concentration and then crystallization.

20

Example 32: (compound 95)

7-Methoxy-4-methyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

32.1. 2-acetyl-5-methoxybenzoic acid

25

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic

acid pretreated with *n*-butyllithium with *N*-methoxy-*N*-methylacetamide. It is used in crude form in the following reaction.

5 **32.2. 7-Methoxy-4-methyl-2*H*-phthalazin-1-one**

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-acetyl-5-methoxybenzoic acid with hydrazine hydrate.

m.p. = 202°C (Mettler FP62)

10 LC/MS: MH^+ = 191 (Rt = 5.73 minutes)

1H NMR δ in ppm (DMSO *d* 6): 2.50 (s, 3H); 3.96 (s, 3H); 7.52 (dd, J_1 = 8.8 Hz, J_2 = 2.7 Hz, 1H); 7.66 (d, J = 2.7 Hz, 1H); 7.90 (d, J = 8.8 Hz, 1H); 12.35 (s, 1H, NH).

15

32.3. 1-Chloro-7-methoxy-4-methylphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-methyl-2*H*-phthalazin-1-one with phosphoryl chloride.

20 LC/MS: MH^+ = 209 (Rt = 6.26 minutes)

1H NMR δ in ppm (DMSO *d* 6): 2.92 (s, 3H); 4.06 (s, 3H); 7.54 (d, J = 2.5 Hz, 1H); 7.77 (dd, J_1 = 9.2 Hz, J_2 = 2.5 Hz, 1H); 8.31 (d, J = 9.2 Hz, 1H).

32.4. 7-Methoxy-4-methyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-methylphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 33: (compound 97)

4-(2,5-dimethoxyphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

33.1. 2-(2,5-dimethoxybenzoyl)-5-methoxybenzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 2,5-dimethoxy-N-methoxy-N-methylbenzamide. It is crystallized from diisopropyl ether.

m.p. = 122°C (Mettler FP62)

LC/MS: MNa^+ = 339 (Rt = 7.40 minutes)

1H NMR δ in ppm (DMSO d 6): 3.50 (s, 3H); 3.73 (s, 3H); 3.86 (s, 3H); 7.02-7.14 (m, 4H); 7.22 (d, J = 2.4 Hz, 1H); 7.29 (d, J = 8.4 Hz, 1H); 12.96 (s, 1H, COOH).

33.2. 4-(2,5-Dimethoxyphenyl)-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 2-(2,5-dimethoxybenzoyl)-5-methoxybenzoic acid with hydrazine hydrate.

m.p. = 208°C (Mettler FP62)

5 LC/MS: MH^+ = 313 (Rt = 7.42 minutes)

1H NMR δ in ppm (DMSO d 6): 3.62 (s, 3H); 3.74 (s, 3H); 3.94 (s, 3H); 6.91 (d, J = 3 Hz, 1H); 7.05-7.15 (m, 2H); 7.22 (d, J = 9 Hz, 1H); 7.40 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.67 (d, J = 2.7 Hz, 1H); 12.67 (s, 1H, 10 NH).

33.3. 1-Chloro-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(2,5-dimethoxyphenyl)-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 140°C (Mettler FP62)

LC/MS: MH^+ = 331 (Rt = 8.36 minutes)

1H NMR δ in ppm (DMSO d 6): 3.61 (s, 3H); 3.77 (s, 3H); 4.05 (s, 3H); 7.0 (d, J = 2.7 Hz, 1H); 7.13-7.21 (m, 2H); 7.55-7.59 (m, 2H); 7.65 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H). 20

33.4. 4-(2,5-dimethoxyphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride 25

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride
 5 is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

Example 34: (compound 102)

**4-(2,4-dimethoxyphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine
 10 dihydrochloride**

34.1. 2-(2,4-dimethoxybenzoyl)-5-methoxybenzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic
 15 acid pretreated with n-butyllithium with 2,4-dimethoxy-N-methoxy-N-methylbenzamide. It is used in crude form in the following reaction.

**34.2. 4-(2,4-Dimethoxyphenyl)-7-methoxy-2H-phthalazin-1-one
 20**

This compound is obtained according to the procedure described in 1.2. by reacting 2-(2,4-dimethoxybenzoyl)-5-methoxybenzoic acid with hydrazine hydrate.

m.p. = 256°C (Mettler FP62)

25 LC/MS: MH^+ = 313 (Rt = 7.49 minutes)

1H NMR δ in ppm (DMSO d 6): 3.69 (s, 3H); 3.86 (s, 3H); 3.94 (s, 3H); 6.65-6.75 (m, 2H); 7.21-7.26 (m, 2H);

7.37-7.43 (m, 1H); 7.66-7.68 (m, 1H); 12.64 (s, 1H, NH).

34.3. 1-Chloro-4-(2,4-dimethoxyphenyl)-7-

5 methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(2,4-dimethoxyphenyl)-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride. m.p. = 177°C (Mettler FP62)

10 LC/MS: $MH^+ = 331$ (Rt = 8.31 minutes)

NMR 1H δ in ppm (DMSO d 6) : 3.68 (s, 3H); 3.89 (s, 3H); 4.05 (s, 3H); 6.75 (dd, $J_1 = 8.3$ Hz, $J_2 = 2.5$ Hz, 1H); 6.80 (d, $J = 2.5$ Hz, 1H); 7.35 (d, $J = 8.3$ Hz, 1H); 7.54-7.64 (m, 3H).

15

34.4. 4-(2,4-dimethoxyphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(2,4-dimethoxyphenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

25

Example 35: (compound 103)

4-(3,5-dimethoxyphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

5 **35.1. 2-(3,5-dimethoxybenzoyl)-5-methoxybenzoic acid**

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 3,5-dimethoxy-N-methoxy-N-methylbenzamide. It is crystallized from

10 diisopropyl ether.

m.p. = 171°C (Mettler FP62)

LC/MS: MH^+ = 317 (Rt = 7.91 minutes)

1H NMR δ in ppm (DMSO d 6): 3.76 (s, 6H); 3.89 (s, 3H); 6.71-6.77 (m, 3H); 7.25 (dd, J_1 = 8.5 Hz, J_2 = 2.5 Hz, 1H); 7.38-7.46 (m, 2H); 13.18 (s, 1H, COOH).

15

35.2. 4-(3,5-Dimethoxyphenyl)-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 2-(3,5-dimethoxybenzoyl)-5-methoxybenzoic acid with hydrazine hydrate.

20

m.p. = 237°C (Mettler FP62)

LC/MS: MH^+ = 313 (Rt = 7.74 minutes)

1H NMR δ in ppm (DMSO d 6): 3.81 (s, 6H); 3.97 (s, 3H); 6.65-6.70 (m, 3H); 7.47 (dd, J_1 = 8.8 Hz, J_2 = 2.7 Hz, 1H); 7.68-7.74 (m, 2H); 12.74 (s, 1H, NH).

25

35.3. 1-Chloro-4-(3,5-dimethoxyphenyl)-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(3,5-dimethoxyphenyl)-
5 7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.
m.p. = 189°C (Mettler FP62)

LC/MS: MH^+ = 331 (Rt = 8.73 minutes)

1H NMR δ in ppm (DMSO d 6): 3.84 (s, 6H); 4.07 (s, 3H);
6.75 (m, 1H); 6.82 (m, 2H); 7.61 (d, J = 2.5 Hz, 1H);
10 7.72 (dd, J_1 = 9 Hz, J_2 = 2.5 Hz, 1H); 8.02 (d, J = 9
Hz, 1H).

**35.4. 4-(3,5-dimethoxyphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-
15 amine dihydrochloride**

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(3,5-dimethoxyphenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride
20 is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

Example 36: (compound 104)

7-methoxy-4-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-(2-phenylethyl)phthalazin-1-amine dihydrochloride

36.1. 5-methoxy-2-(2-phenylpropionyl)benzoic acid

5 This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with *N*-methoxy-*N*-methyl-2-phenylpropionamide. It is used in crude form in the following reaction.

10

36.2. 7-Methoxy-4-(2-phenylethyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-methoxy-2-(2-phenylpropionyl)benzoic acid with hydrazine hydrate.

15 m.p. = 189°C (Mettler FP62)

LC/MS: MH^+ = 281 (Rt = 6.62 minutes)

1H NMR δ in ppm (DMSO *d* 6): 2.98-3.04 (m, 2H); 3.16-3.22 (m, 2H); 3.94 (s, 3H); 7.14-7.30 (m, 5H); 7.48 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.66 (d, J = 2.7 Hz, 1H); 7.99 (d, J = 9 Hz, 1H); 12.40 (s, 1H, NH).

20

36.3. 1-Chloro-7-methoxy-4-(2-phenylethyl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(2-phenylethyl)-2H-phthalazin-1-one with phosphoryl chloride.

25

LC/MS: MH^+ = 299 (Rt = 8.94 minutes)

^1H NMR δ in ppm (DMSO d_6): 3.10-3.15 (m, 2H); 3.54-3.60 (m, 2H); 4.03 (s, 3H); 7.17-7.31 (m, 5H); 7.49 (d, J = 2.5 Hz, 1H); 7.67 (dd, J_1 = 9 Hz, J_2 = 2.5 Hz, 1H); 8.31 (d, J = 9 Hz, 1H).

5

36.4. 7-methoxy-4-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-(2-phenyl-ethyl)phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(2-phenylethyl)phthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

15

Example 37: (compound 106)

7-Fluoro-4-(4-fluorophenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

20 37.1. 7-Fluoro-4-(4-fluorophenyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 5-fluoro-2-(4-fluorobenzoyl)benzoic acid with hydrazine hydrate.

m.p. = 206°C (Mettler FP62)

25 LC/MS: MH^+ = 259 (R_t = 7.64 minutes)

37.2. 1-Chloro-7-fluoro-4-(4-fluorophenyl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-fluoro-4-(4-fluorophenyl)-2H-phthalazin-1-one with phosphoryl chloride.

5 m.p. = 195°C (Mettler FP62)

LC/MS: MH^+ = 277 (Rt = 7.90 minutes)

1H NMR δ in ppm (DMSO d 6): 7.45-7.52 (m, 2H), 7.78-7.84 (m, 2H); 8.03-8.19 (m, 3H).

10 **37.3. 7-Fluoro-4-(4-fluorophenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine**

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-fluoro-4-(4-fluorophenyl)phthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 38: (compound 109)

7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-4-(pyridin-3-yl)phthalazin-1-amine trihydrochloride

20 **38.1. 5-methoxy-2-pyridin-3-ylbenzoic acid**

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with N-methoxy-N-methylnicotinamide. After precipitation in aqueous
25 phase at pH 4, followed by filtration and drying, a beige-coloured powder is obtained.

m.p. = 178°C (Mettler FP62)

LC/MS: MH^+ = 258 (Rt = 5.59 minutes)

1H NMR δ in ppm (DMSO d 6): 3.90 (s, 3H); 7.29 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.43-7.56 (m, 3H); 7.97 (m, 1H);
5 8.73-8.77 (m, 2H); 13.31 (s, 1H, COOH).

38.2. 7-Methoxy-4-(pyridin-3-yl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 5-methoxy-2-pyridin-3-ylbenzoic acid with hydrazine hydrate.
10

m.p. = 260°C (Köfler)

LC/MS: MH^+ = 254 (Rt = 5.43 minutes)

1H NMR δ in ppm (DMSO d 6): 3.97 (s, 3H); 7.49 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.59-7.64 (m, 2H); 7.76 (d, J = 2.7 Hz, 1H); 8.02-8.06 (m, 1H); 8.72-8.80 (m, 2H); 12.90
15 (s, 1H, NH).

38.3. 1-Chloro-7-methoxy-4-(pyridin-3-yl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-(pyridin-3-yl)-2H-phthalazin-1-one with phosphoryl chloride.
20

m.p. = 180°C (Mettler FP62)

LC/MS: MH^+ = 272 (Rt = 6.26 minutes)

1H NMR δ in ppm (DMSO d 6): 4.08 (s, 3H); 7.51-7.76 (m, 3H); 7.96 (d, J = 9 Hz, 1H); 8.15-8.20 (m, 1H); 8.80-9.0 (m, 2H).
25

38.4. 7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-4-(pyridin-3-yl)phthalazin-1-amine trihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-(pyridin-3-yl)phthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The trihydrochloride is obtained after treatment with a solution of hydrogen chloride in isopropyl alcohol.

10

Example 39: (compound 111)

4-(biphenyl-4-yl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

15 39.1. 2-(biphenyl-4-carbonyl)-5-methoxybenzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 4-phenyl-N-methoxy-N-methylbenzamide.

20 m.p. = 200°C (Mettler FP62)

LC/MS: MH⁺ = 333 (Rt = 9.16 minutes)

¹H NMR δ in ppm (DMSO d 6): 3.90 (s, 3H); 7.28 (dd, J₁ = 8.5 Hz, J₂ = 2.5 Hz, 1H); 7.41-7.54 (m, 5H); 7.69-7.82 (m, 6H); 13.2 (s, 1H, COOH).

25

39.2. 4-(Biphenyl-4-yl)-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 2-(biphenyl-4-carbonyl)-5-methoxybenzoic acid with hydrazine hydrate.

LC/MS: MH^+ = 329 (Rt = 9.31 minutes)

5 1H NMR δ in ppm (DMSO d 6): 3.98 (s, 3H); 7.42-7.56 (m, 4H), 7.66-7.88 (m, 8H); 12.81 (s, 1H, NH).

39.3. 4-(Biphenyl-4-yl)-1-chloro-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(biphenyl-4-yl)-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 177°C (Mettler FP62)

LC/MS: MH^+ = 347 (Rt = 10.25 minutes)

15 1H NMR δ in ppm (DMSO d 6): 4.08 (s, 3H); 7.44-7.58 (m, 3H), 7.63 (d, J = 2.5 Hz, 1H); 7.73 (dd, J_1 = 9 Hz, J_2 = 2.5 Hz, 1H); 7.79-7.95 (m, 6H); 8.05 (d, J = 9 Hz, 1H).

39.4. 7-methoxy-4-(4-phenylphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 4-(biphenyl-4-yl)-1-chloro-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

Example 40: (compound 117)

4-(3,4-dimethylphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

5 **40.1. 2-(3,4-dimethylbenzoyl)-5-methoxybenzoic acid**

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 3,4-dimethyl-N-methoxy-N-methylbenzamide.

10 m.p. = 173°C (Mettler FP62)

LC/MS: MH^+ = 285 (Rt = 8.37 minutes)

1H NMR δ in ppm (DMSO d 6): 2.24 (s, 3H); 2.28 (s, 3H); 3.88 (s, 3H); 7.18-7.55 (m, 6H); 13.07 (s, 1H, COOH).

15 **40.2. 4-(3,4-Dimethylphenyl)-7-methoxy-2H-phthalazin-1-one**

This compound is obtained according to the procedure described in 1.2. by reacting 2-(3,4-dimethylbenzoyl)-5-methoxybenzoic acid with hydrazine hydrate.

20 m.p. = 241°C (Mettler FP62)

LC/MS: MH^+ = 281 (Rt = 8.54 minutes)

1H NMR δ in ppm (DMSO d 6): 2.32 (s, 3H); 2.33 (s, 3H); 3.97 (s, 3H); 7.26-7.35 (m, 3H); 7.47 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.66 (d, J = 9 Hz, 1H); 7.74 (d, J = 2.7 Hz, 1H); 12.73 (s, 1H, NH).

25

40.3. 1-Chloro-4-(3,4-dimethylphenyl)-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(3,4-dimethylphenyl)-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 204°C (Mettler FP62)

LC/MS: MH^+ = 299 (Rt = 9.47 minutes)

1H NMR δ in ppm (DMSO d 6): 2.35 (s, 3H); 2.36 (s, 3H); 4.06 (s, 3H); 7.35-7.48 (m, 3H); 7.59 (d, J = 2.5 Hz, 1H); 7.70 (dd, J_1 = 9 Hz, J_2 = 2.5 Hz, 1H); 7.98 (d, J = 9 Hz, 1H).

40.4. 4-(3,4-dimethylphenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(3,4-dimethylphenyl)-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in isopropanol, followed by crystallization from ethyl acetate.

Example 41: (compound 136)

7-methoxy-4-phenoxyethyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

41.1. 5-methoxy-2-(2-phenoxyacetyl)benzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with *n*-butyllithium with *N*-methoxy-*N*-methyl-2-phenoxyacetamide. The product is used in crude form in the following reaction.

41.2. 7-Methoxy-4-phenoxyethyl-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 5-methoxy-2-(2-phenoxyacetyl)benzoic acid with hydrazine hydrate.

m.p. = 192°C (Mettler FP62)

LC/MS: MH^+ = 283 (Rt = 7.91 minutes)

1H NMR δ in ppm (DMSO *d* 6): 3.96 (s, 3H); 5.31 (s, 2H); 6.96-7.10 (m, 3H); 7.29-7.36 (m, 2H); 7.55 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.68 (d, J = 2.7 Hz, 1H); 7.98 (d, J = 9 Hz, 1H); 12.69 (s, 1H, NH).

41.3. 1-Chloro-7-methoxy-4-phenoxyethylphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-4-phenoxyethyl-2H-phthalazin-1-one with phosphoryl chloride.

LC/MS: MH^+ = 301 (Rt = 8.90 minutes)

1H NMR δ in ppm (DMSO *d* 6): 4.06 (s, 3H); 5.73 (s, 2H); 6.96-7.03 (m, 1H); 7.09-7.13 (m, 2H); 7.29-7.36 (m,

2H); 7.58 (d, $J = 2.5$ Hz, 1H); 7.81 (dd, $J_1 = 9$ Hz, $J_2 = 2.5$ Hz, 1H); 8.37 (d, $J = 9$ Hz, 1H).

41.4. 7-methoxy-4-phenoxyethyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-7-methoxy-4-phenoxyethylphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether, followed by crystallization from diisopropyl ether.

15 Example 42: (compound 137)

4,7-diphenyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-phthalazin-1-amine dihydrochloride

42.1. 7-Hydroxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-4-phenylphthalazin-1-amine

20 A mixture of 597 mg (1.25 mmol) of 7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-4-phenylphthalazin-1-amine (compound 1) and pyridinium hydrochloride is heated at 210°C for 45 minutes. The reaction medium is cooled and 1N sodium hydroxide solution is then added. A precipitate forms, which is washed with water and with dichloromethane, and then

dried under reduced pressure. 500 mg of a beige-coloured powder are obtained.

LC/MS: MH^+ = 461 (R_t = 5.30 minutes)

1H NMR δ in ppm (DMSO d_6): 1.64-1.73 (m, 2H); 1.90-2.03
5 (m, 2H); 2.10-2.22 (m, 2H); 2.85-2.95 (m, 2H); 3.66 (s, 2H); 4.10-4.18 (m, 1H); 5.90-6.0 (m, 1H, OH); 6.60-6.64 (m, 2H); 7.20-7.24 (d, J = 9.7 Hz, 1H, NH); 7.39-7.57 (m, 9H); 7.82-7.94 (m, 4H).

10 **42.2. 1-[1-(naphthalen-2-ylmethyl)piperidin-4-yl-amino]-4-phenyl-7-trifluoromethanesulfonyloxyphthalazin-6-yl**

558 mg (1.5 mmol) of N-phenyltrifluoromethanesulfonimide ($(CF_3SO_2)_2NC_6H_5$) and
15 0.17 mL of triethylamine are added to a solution of 480 mg (1.04 mmol) of 7-hydroxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-4-phenylphthalazin-1-amine in 6 mL of dichloromethane. The mixture is stirred at room temperature under argon for 2 days. It is hydrolysed
20 with aqueous ammonium chloride solution and then extracted with dichloromethane. The organic phase is dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. A brown oil is obtained, which is used as obtained in the following
25 reaction.

42.3. 4,7-diphenyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-phthalazin-1-amine dihydrochloride

0.5 mL of aqueous 2N sodium carbonate solution, 70 mg
5 (0.57 mmol) of phenylboronic acid and 18 mg of tetrakis
palladium are added to a solution of 0.5 mmol of 1-[1-(naphthalen-2-ylmethyl)piperidin-4-yl-amino]-4-phenyl-
7-trifluoromethanesulfonyloxyphthalazin-6-yl in 4 ml of
toluene. The mixture is stirred at 100°C for 6 hours in
10 a stoppered tube under argon. 1N sodium hydroxide
solution is added to the cooled reaction medium, and
the mixture is extracted with ethyl acetate. The
organic phase is dried over anhydrous sodium sulfate,
filtered and evaporated under reduced pressure. After
15 purification by column chromatography (100/0 to 90/10
(v/v) dichloromethane/methanol), 150 mg of product are
obtained.

LC/MS: MH^+ = 521 (R_t = 6.48 minutes)

1H NMR δ in ppm (DMSO d_6): 1.70-1.90 (m, 2H); 2.08-2.30
20 (m, 4H); 2.90-3.05 (m, 2H); 3.72 (s, 2H); 4.30-4.40 (m,
1H); 7.40 (d, 1H, NH); 7.48-7.70 (m, 11H); 7.82-7.97
(m, 7H); 8.18 (d, J = 9 Hz, 1H); 8.25 (s, 1H).

The dihydrochloride is obtained after treatment with a
solution of hydrogen chloride in diethyl ether.

Example 43: (compound 142)

4-(4-methoxyphenyl)-6-methyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

43.1. 2-(4-methoxybenzoyl)-4-methylbenzoic acid

5 This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-4-methylbenzoic acid pretreated with n-butyllithium with 4-methoxy-N-methoxy-N-methyl-4-benzamide. It is used in crude form in the following reaction.

10

43.2. 4-(4-Methoxyphenyl)-6-methyl-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-(4-methoxybenzoyl)-4-methylbenzoic acid with hydrazine

15 hydrate.

m.p. = 245°C (Mettler FP62)

LC/MS: MH^+ = 267 (Rt = 7.63 minutes)

1H NMR δ in ppm (DMSO d 6): 2.33 (s, 3H); 3.86 (s, 3H);

7.10-7.13 (m, 2H); 7.48-7.55 (m, 3H); 7.70 (d, J = 8

20 Hz, 1H); 8.24 (d, J = 8 Hz, 1H); (NH not detected).

43.3. 1-Chloro-4-(4-methoxyphenyl)-6-methylphthalazine

25 This compound is obtained according to the procedure described in 1.3. by reacting 4-(4-methoxyphenyl)-6-methyl-2H-phthalazin-1-one with phosphoryl chloride.

LC/MS: MH^+ = 285 (Rt = 8.70 minutes)

^1H NMR δ in ppm (DMSO d_6): 2.58 (s, 3H); 3.90 (s, 3H); 7.16-7.23 (m, 2H); 7.66-7.73 (m, 2H); 7.85 (d, $J = 1.5$ Hz, 1H); 8.03 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.5$ Hz, 1H); 8.28 (d, $J = 8.5$ Hz, 1H).

5

43.4. 4-(4-methoxyphenyl)-6-methyl-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

This compound is obtained according to the procedure described in 1.4. by reacting 1-chloro-4-(4-methoxyphenyl)-6-methylphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

Example 44: (compound 143)

7-chloro-4-(4-methoxyphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

44.1. 5-chloro-2-(4-methoxybenzoyl)benzoic acid

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-chlorobenzoic acid pretreated with *n*-butyllithium with 4-methoxy-*N*-methoxy-*N*-methyl-benzamide. It is used in crude form in the following reaction.

44.2. 7-Chloro-4-(4-methoxyphenyl)-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 5-chloro-2-(4-methoxybenzoyl)benzoic acid with hydrazine hydrate.

m.p. = 220°C (Mettler FP62)

5 LC/MS: MH^+ = 286 (Rt = 8.12 minutes)

1H NMR δ in ppm (DMSO d 6): 3.86 (s, 3H); 7.09-7.15 (m, 2H); 7.50-7.57 (m, 2H); 7.74 (d, J = 8.7 Hz, 1H); 7.96 (dd, J_1 = 8.7 Hz, J_2 = 2.2 Hz, 1H); 8.28 (d, J = 2.2 Hz, 1H); 13.0 (s, 1H, NH).

10

44.3. 1,7-Dichloro-4-(4-methoxyphenyl)phthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 7-chloro-4-(4-methoxyphenyl)-2H-phthalazin-1-one with phosphoryl

15 chloride.

LC/MS: MH^+ = 305 (Rt = 9.34 minutes)

1H NMR δ in ppm (DMSO d 6): 3.90 (s, 3H); 7.17-7.23 (m, 2H); 7.68-7.74 (m, 2H); 8.10 (d, J = 9 Hz, 1H); 8.17 (dd, J_1 = 9 Hz, J_2 = 2 Hz, 1H); 8.39 (d, J = 2 Hz, 1H).

20

44.4. 7-chloro-4-(4-methoxyphenyl)-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure

25 described in 1.4. by reacting 1,7-dichloro-4-(4-methoxyphenyl)phthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained

after treatment with a solution of hydrogen chloride in diethyl ether, followed by crystallization from diisopropyl ether.

5 **Example 45: (compound 145)**

4-(4-bromophenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

45.1. 2-(4-Bromobenzoyl)-5-methoxybenzoic acid

10 This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 4-bromo-N-methoxy-N-methylbenzamide. It is used in crude form in the following reaction.

15

45.2. 4-(4-Bromophenyl)-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting unpurified 2-(4-bromobenzoyl)-5-methoxybenzoic acid with hydrazine
20 hydrate.

m.p. = 275°C (Mettler FP62)

LC/MS: MH^+ = 333 (Rt = 8.47 minutes)

1H NMR δ in ppm (DMSO d 6): 3.97 (s, 3H); 7.48 (dd, J_1 = 9 Hz, J_2 = 2.7 Hz, 1H); 7.52-7.58 (m, 2H); 7.64 (d, J =
25 9 Hz, 1H); 7.74-7.79 (m, 3H); 12.83 (s, 1H, NH).

45.3. 4-(4-Bromophenyl)-1-chloro-7-methoxyphthalazine

This compound is obtained according to the procedure described in 1.3. by reacting 4-(4-bromophenyl)-7-methoxy-2*H*-phthalazin-1-one with phosphoryl chloride.
m.p. = 205°C (Mettler FP62)

5 LC/MS: MH^+ = 351 (Rt = 9.38 minutes)

1H NMR δ in ppm (DMSO *d* 6): 4.07 (s, 3H); 7.63 (d, *J* = 2.5 Hz, 1H); 7.65-7.69 (m, 2H); 7.72 (dd, *J*₁ = 9 Hz, *J*₂ = 2.5 Hz, 1H); 7.81-7.87 (m, 2H); 7.96 (d, *J* = 9 Hz, 1H).

10

45.4. 4-(4-Bromophenyl)-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 4-(4-bromophenyl)-1-chloro-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine. The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

20

Example 46: (compound 17)

7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-5-phenylphthalazin-1-amine dihydrochloride

46.1. Methyl 2-formyl-3-hydroxy-5-methoxybenzoate

25 A solution of 5.1 g (0.3 mmol) of methyl 2-formyl-3,5-methoxybenzoate in 50 mL of dichloromethane is stirred at -10°C, followed by dropwise addition of 23 mL of a

solution of boron tribromide in dichloromethane. The mixture is stirred at -10°C for 1 hour and is then hydrolysed with 100 mL of water. The organic phase is washed with water, dried over anhydrous sodium sulfate, 5 filtered and evaporated under reduced pressure. The residue is purified on a column of silica (eluent: 7/3 v/v cyclohexane/ethyl acetate). 4 g of a beige-coloured product are obtained.

^1H NMR δ in ppm (DMSO d_6): 3.83 (s, 3H); 3.86 (s, 3H); 10 6.66 (d, $J = 2.5$ Hz, 1H); 6.73 (d, $J = 2.5$ Hz, 1H); 10.20 (s, 1H, CHO); 11.8 (s, 1H, OH).

46.2. Methyl 2-formyl-5-methoxy-3-trifluoromethanesulfonyloxybenzoate

15 A solution of 1 g (4.7 mmol) of methyl 2-formyl-3-hydroxy-5-methoxybenzoate in 20 mL of tetrahydrofuran is stirred at room temperature under nitrogen, followed by addition of 200 mg of sodium hydride as a 60% suspension in oil. The mixture is stirred for 30 20 minutes and 1.7 g (4.8 mmol) of N-phenyltrifluoromethanesulfonimide ($(\text{CF}_3\text{SO}_2)_2\text{NC}_6\text{H}_5$) are then added portionwise. The reaction medium is stirred for 24 hours and then hydrolysed with aqueous ammonium chloride solution and extracted with ethyl acetate. The 25 organic phase is washed with water and with brine, dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The product, in the

form of a brown oil, is used without purification in the following reaction.

LC/MS: MH^+ = 343 (Rt = 9.07 minutes)

5 **46.3. 2-Formyl-5-methoxy-3-phenylbenzoic acid**

A solution of about 2.3 mmol of methyl 2-formyl-5-methoxy-3-trifluoromethanesulfonyloxybenzoate in 10 mL of toluene is stirred under argon, and 330 mg (2.7 mmol) of phenylboronic acid, 84 mg of tetrakis
10 palladium and 2.5 mL of aqueous 2N sodium carbonate solution are added. The mixture is stirred at 110°C for 6 hours in a stoppered tube under argon. Water is added to the cooled reaction medium, and the mixture is washed with ethyl acetate and, after acidification (1N
15 HCl), is then extracted with dichloromethane. The organic phase is dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The product, in the form of a brown solid, is used without purification in the following reaction.

20 LC/MS: MH^+ = 257 (Rt = 7.76 minutes)

46.4. 7-Methoxy-5-phenyl-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 2-formyl-5-methoxy-3-
25 phenylbenzoic acid with hydrazine hydrate.

m.p. = 139°C (Mettler FP62)

LC/MS: MH^+ = 253 (Rt = 7.62 minutes)

^1H NMR δ in ppm (DMSO *d* 6): 3.99 (s, 3H); 7.41 (d, J = 2.5 Hz, 1H); 7.48-7.61 (m, 5H); 7.70 (d, J = 2.5 Hz, 1H); 7.96 (s, 1H); 12.69 (s, 1H, NH).

5 **46.5. 1-Chloro-7-methoxy-5-phenylphthalazine**

This compound is obtained according to the procedure described in 1.3. by reacting 7-methoxy-5-phenyl-2H-phthalazin-1-one with phosphoryl chloride.

m.p. = 146°C (Mettler FP62)

10 LC/MS: MH^+ = 271 (Rt = 8.58 minutes)

^1H NMR δ in ppm (DMSO *d* 6): 4.08 (s, 3H); 7.54-7.62 (m, 6H); 7.67 (d, J = 2.7 Hz, 1H); 9.20 (s, 1H).

15 **46.6. 7-Methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]-5-phenylphthalazin-1-amine dihydrochloride**

This compound is obtained according to the procedure described in 2.4. by reacting 1-chloro-7-methoxy-5-phenylphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

20 LC/MS: MH^+ = 475 (Rt = 5.69 minutes)

^1H NMR δ in ppm (DMSO *d* 6): 1.65-1.80 (m, 2H); 2.03-2.25 (m, 4H); 2.90-3.03 (m, 2H); 3.70 (s, 2H); 4.0 (s, 3H); 4.20-4.30 (m, 1H); 7.03 (d, 1H, NH); 7.36 (d, J = 2.5 Hz, 1H); 7.48-7.58 (m, 8H); 7.76 (d, J = 2.5 Hz, 1H);
25 7.84-7.92 (m, 4H); 8.52 (s, 1H).

The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

Example 47: (compound 147)

4-benzyloxymethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

5 **47.1. 2-(2-Benzyloxyacetyl)-5-methoxybenzoic acid**

This compound is synthesized according to the method described in 3.2. by reacting 2-bromo-5-methoxybenzoic acid pretreated with n-butyllithium with 2-benzyloxy-N-methoxy-N-methylacetamide. The product is used in crude
10 form in the following reaction.

47.2. 4-Benzyloxymethyl-7-methoxy-2H-phthalazin-1-one

This compound is obtained according to the procedure described in 1.2. by reacting 2-(2-benzyloxyacetyl)-5-
15 methoxybenzoic acid with hydrazine hydrate.

m.p. = 140°C (Mettler FP62)

LC/MS: MH^+ = 297 (Rt = 7.80 minutes)

1H NMR δ in ppm (DMSO d 6): 3.95 (s, 3H); 4.58 (s, 2H);
4.73 (s, 2H); 7.25-7.37 (m, 5H); 7.53 (dd, J_1 = 9 Hz, J_2
20 = 2.7 Hz, 1H); 7.66 (d, J = 2.7 Hz, 1H); 8.04 (d, J = 9
Hz, 1H); 12.59 (s, 1H, NH).

47.3. 4-Benzyloxymethyl-1-chloro-7-methoxyphthalazine

This compound is obtained according to the procedure
25 described in 1.3. by reacting 4-benzyloxymethyl-7-methoxy-2H-phthalazin-1-one with phosphoryl chloride.

This oily compound is used as obtained in the following reaction.

47.4. 4-Benzyloxymethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride

This compound is obtained according to the procedure described in 1.4. by reacting 4-benzyloxymethyl-1-chloro-7-methoxyphthalazine with 4-amino-1-(naphthalen-2-ylmethyl)piperidine.

^1H NMR δ in ppm (DMSO d_6): 1.65-1.75 (m, 2H); 2.0-2.25 (m, 4H); 2.90-3.0 (m, 2H); 3.70 (s, 2H); 3.97 (s, 3H); 4.20-4.30 (m, 1H); 4.55 (s, 2H); 4.90 (s, 2H); 7.02 (d, 1H, NH); 7.30-7.36 (m, 5H); 7.45-7.56 (m, 4H); 7.73 (d, $J = 2.2$ Hz, 1H); 7.84-7.92 (m, 4H); 8.06 (d, $J = 9$ Hz, 1H).

The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

20 Example 48: (compound 148)

4-Hydroxymethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine

A solution of 120 mg of 4-benzyloxymethyl-7-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]phthalazin-1-amine in 4 mL of dichloromethane is stirred under nitrogen at 0°C , followed by dropwise addition of 2.3 mL of a molar solution of boron trichloride in

dichloromethane. The reaction medium is stirred for 1 hour at 0°C and then for 30 minutes at room temperature. It is hydrolysed with aqueous sodium bicarbonate solution and extracted with
5 dichloromethane. The organic phase is washed with water, dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue is purified on a column of silica (eluent: 100/0 to 85/15 v/v dichloromethane/methanol). 58 mg of product are
10 obtained in the form of a beige-coloured powder.
m.p. = 102°C (Köfler)
LC/MS: MH^+ = 429 (Rt = 4.78 minutes)
 1H NMR δ in ppm (DMSO d 6): 1.60-1.80 (m, 2H); 2.0-2.30 (m, 4H); 2.90-3.0 (m, 2H); 3.72 (s, 2H); 3.97 (s, 3H);
15 4.18-4.30 (m, 1H); 4.84 (d, J = 5.5 Hz, 2H); 5.29 (t, J = 5.5 Hz, 1H); 6.95 (d, J = 7.5 Hz, 1H, NH); 7.45-7.60 (m, 4H); 7.71(d, J = 2.5 Hz, 1H); 7.84-7.93 (m, 4H); 8.05 (d, J = 9.2 Hz, 1H).
The dihydrochloride is obtained after treatment with a
20 solution of hydrogen chloride in diethyl ether.

Example 49: (compound 18)

N-[1-(3-cyanophenylmethyl)-piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine

49.1. 7-Methoxy-4-(4-methoxyphenyl)-N-(piperidin-4-yl)-phthalazin-1-amine

The manipulation is performed under an inert atmosphere (nitrogen).

1 g of 10% palladium-on-charcoal and 100 mL of water are introduced into a 500 mL three-necked flask. A solution, prepared beforehand, of 13.3 g of N-(1-benzylpiperidin-4-yl)-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 7) in 50 mL of ethanol and 4.4 mL of formic acid is added dropwise over 1 hour, to this mixture with stirring at 85°C. The reaction mixture is stirred at reflux for 2 hours. After cooling to room temperature, the ethanol is evaporated off under reduced pressure. The mixture is then basified to pH 12 with 2N sodium hydroxide solution and is then extracted with dichloromethane. The organic phase is washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The yellow oil obtained is concreted in diisopropyl ether to give a white solid. After filtration and drying under vacuum in the presence of phosphorus pentoxide, 10.29 g of 7-methoxy-4-(4-methoxyphenyl)-N-(piperidin-4-yl)-phthalazin-1-amine are obtained (97% yield).

m.p. = 143°C (Mettler FP62)

LC/MS: MH^+ = 365 (Rt = 4.88 minutes)

1H NMR δ in ppm (DMSO d 6): 1.5-1.65 (m, 2H); 2.0-2.1 (m, 2H); 2.6-2.7 (m, 2H); 3.0-3.1 (m, 2H); 3.3 (s, 1H, 5 NH); 3.85 (s, 3H); 3.98 (s, 3H); 4.2-4.3 (m, 1H); 7.0 (d, J = 7.5 Hz, 1H); 7.10 (d, J = 8.5 Hz, 2H); 7.42 (dd, J_1 = 9.2 Hz, J_2 = 2.5 Hz, 1H); 7.52 (d, J = 8.5 Hz, 2H); 7.75 (d, J = 9.2 Hz, 1H); 7.78 (d, J = 2.5 Hz, 1H).

10

49.2. N-[1-(3-Cyanobenz)-piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine

183 mg (1.4 mmol) of 3-cyanobenzaldehyde are added to a solution of 500 mg (1.4 mmol) of 7-methoxy-4-(4-methoxyphenyl)-N-(piperidin-4-yl)phthalazin-1-amine in 15 5 mL of 1,2-dichloroethane. The mixture is stirred for 30 minutes under nitrogen, and 378 mg (1.8 mmol) of sodium triacetoxyborohydride are then added. The reaction medium is stirred for 16 hours at room 20 temperature and then hydrolysed with water and 1N sodium hydroxide solution. The dichloromethane extract is washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue is 25 purified on a column of silica (eluent: 95/5 (v/v) dichloromethane/methanol). After crystallization from

diisopropyl ether, 300 mg of a white powder are obtained.

m.p. = 115°C (Mettler FP62)

LC/MS: MH^+ = 480 (Rt = 4.24 minutes)

5 1H NMR δ in ppm (DMSO d 6): 1.64-1.80 (m, 2H); 2.03-2.28 (m, 4H); 2.85-2.95 (m, 2H); 3.62 (s, 2H); 3.86 (s, 3H); 3.99 (s, 3H); 4.20-4.33 (m, 1H); 7.0 (d, 1H, NH); 7.10 (d, J = 8.5 Hz, 2H); 7.44 (dd, J_1 = 9.2 Hz, J_2 = 2.5 Hz, 1H); 7.54 (d, J = 8.5 Hz, 2H); 7.60 (d, J = 9.2 Hz, 10 1H); 7.70-8.80 (m, 5H).

This reductive amination method was used with several commercially available aldehydes or aldehydes already described in the literature. The synthesized compounds are described in the table.

15

Example 50: (compounds 56, 149 and 150)

7-methoxy-4-(4-methoxyphenyl)-N-1-[1-(naphthalen-2-yl-ethyl)piperidin-4-yl]phthalazin-1-amine (racemic and enantiomers)

20 232 mg (1.4 mmol) of 1-naphthalen-2-ylethanone and 0.5 mL of titanium tetraisopropoxide are added to a solution of 500 mg (1.4 mmol) of 7-methoxy-4-(4-methoxyphenyl)-N-(piperidin-4-yl)phthalazin-1-amine in 5 mL of ethanol. The mixture is stirred for 18 hours 25 under nitrogen at room temperature, followed by addition of 58 mg (0.9 mmol) of sodium cyanoborohydride as a solution in 2 mL of ethanol. The reaction medium

is stirred for 18 hours at room temperature and then filtered. The filtrate is evaporated to dryness and then purified by chromatography on a column of silica (eluent: 100/0 to 90/10 v/v dichloromethane/methanol).

- 5 After crystallization from diisopropyl ether, 480 mg of a white powder are obtained.

The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether followed by crystallization from diisopropyl ether.

- 10 The enantiomers are separated by liquid chromatography on a Chiralpak AD chiral phase (eluent: 60/40 (v/v) isohexane/ethanol). Their absolute configurations were not determined. These products contain a small amount of residual isohexane.

15

(-)-7-Methoxy-4-(4-methoxyphenyl)-N-1-[1-(naphthalen-2-ylethyl)piperidin-4-yl]phthalazin-1-amine

$[\alpha]_D^{20} = -24$ (c = 0.15, dichloromethane)

m.p. = 136°C (Mettler FP62)

- 20 LC/MS: $MH^+ = 519$ (Rt = 5.76 minutes)

1H NMR δ in ppm ($CDCl_3$): 1.45 (d, J = 6.7 Hz, 3H); 1.64-1.79 (m, 2H); 2.10-2.35 (m, 4H); 2.80-2.90 (m, 1H); 3.08-3.15 (m, 1H); 3.65-3.75 (m, 1H, CH); 3.84 (s, 3H); 3.94 (s, 3H); 4.30-4.40 (m, 1H); 5.13 (d, J = 7.2, 1H, NH); 6.98 (d, J = 8.7 Hz, 2H); 7.11 (d, J = 2.2 Hz, 1H, H-1 naphthyl); 7.27 (dd, $J_1 = 9.2$ Hz, $J_2 = 2.5$ Hz, 1H);

25

7.40-7.45 (m, 2H); 7.52-7.60 (m, 3H); 7.71-7.80 (m, 4H); 7.87 (d, $J = 9.2$ Hz, 1H).

(+)-7-Methoxy-4-(4-methoxyphenyl)-N-1-[1-(naphthalen-2-ylethyl)piperidin-4-yl]phthalazin-1-amine

$[\alpha]_D^{20} = +17$ ($c = 0.18$, dichloromethane)

m.p. = 132°C (Mettler FP62)

LC/MS: $\text{MH}^+ = 519$ ($R_t = 5.76$ minutes)

^1H NMR δ in ppm (CDCl_3): 1.53 (d, $J = 6.7$ Hz, 3H); 1.63-1.80 (m, 2H); 2.15-2.42 (m, 4H); 2.90-3.0 (m, 1H); 3.17-3.27 (m, 1H); 3.65-3.75 (m, 1H, CH); 3.90 (s, 3H); 4.02 (s, 3H); 4.34-4.44 (m, 1H); 4.76 (d, $J = 7.2$, 1H, NH); 7.01 (d, $J = 2.2$ Hz, 1H, H-1 naphthyl); 7.05 (d, $J = 8.7$ Hz, 2H); 7.34 (dd, $J_1 = 9.2$ Hz, $J_2 = 2.5$ Hz, 1H); 7.46-7.52 (m, 2H); 7.58-7.66 (m, 3H); 7.74-7.88 (m, 4H); 7.96 (d, $J = 9.2$ Hz, 1H).

Example 51: (compound 112)

N-[1-(4-hydroxymethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride

This product is obtained by reduction of the corresponding methyl ester (compound 107), which was prepared by the reductive amination method described in 49.2, using methyl 4-formylbenzoate.

A solution of 400 mg (0.78 mmol) of methyl {4-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}carboxylate

compound 107) in 6 mL of tetrahydrofuran is added slowly to a suspension of 59 mg (1.6 mmol) of lithium aluminium hydride in 6 mL of tetrahydrofuran, stirred at 0°C. The reaction medium is stirred at 0°C for 1
5 hour and then hydrolysed with 0.1 mL of 1N sodium hydroxide solution, 2 mL of water and 0.1 mL of 1N sodium hydroxide solution. It is extracted with dichloromethane. The organic phase is washed with saturated aqueous sodium chloride solution, dried over
10 anhydrous sodium sulfate and then evaporated under reduced pressure. The residue is purified on a column of silica (eluent: 85/15 (v/v) dichloromethane/methanol). After crystallization from diisopropyl ether, 220 mg of a white powder are
15 obtained.

m.p. = 139°C (Mettler FP62)

LC/MS: MH^+ = 485 (Rt = 4.99 minutes)

1H NMR δ in ppm (DMSO d 6): 1.60-1.80 (m, 2H); 2.03-2.20 (m, 4H); 2.85-2.96 (m, 2H); 3.51 (s, 2H); 3.85 (s, 3H);
20 3.97 (s, 3H); 4.20-4.30 (m, 1H); 4.49 (d, J = 5.7 Hz, 2H); 5.13 (t, J = 5.7 Hz, 1H); 6.98 (d, J = 7.5 Hz, 1H, NH); 7.10 (d, J = 8.7 Hz, 2H); 7.30 (s, 4H); 7.42 (dd, J_1 = 9.2 Hz, J_2 = 2.5 Hz, 1H); 7.50 (d, J = 8.7 Hz, 2H); 7.72-7.77 (m, 2H).

25 The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

Example 52: (compound 113)

N-[1-(4-aminomethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine trihydrochloride

This product is obtained by reduction of N-[1-(4-cyanobenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine (compound 108), which was prepared via the reductive amination method described in 49.2, using 4-cyanobenzaldehyde.

8 mL of tetrahydrofuran are stirred at 10°C and 394 mg (10 mmol) of sodium borohydride are added. Next, 0.8 mL (10 mmol) of trifluoroacetic acid is added dropwise. The reaction medium is stirred for 10 minutes, and a solution of 1 g (2 mmol) of N-[1-(4-cyanobenzyl)-piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine in 8 mL of tetrahydrofuran is then introduced. The reaction medium is stirred overnight at room temperature and is then concentrated under reduced pressure. 10 mL of 10% hydrochloric acid are added and the solution is refluxed for 1 hour 30 minutes. After cooling, the reaction medium is washed with diethyl ether and then basified with 1N sodium hydroxide solution and extracted with ethyl acetate. The organic phase is washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. After crystallization from

diisopropyl ether, 850 mg of a white powder are obtained.

m.p. = 203°C (Mettler FP62)

LC/MS: MH^+ = 484 (Rt = 4.42 minutes)

5 1H NMR δ in ppm (DMSO d 6): 1.60-1.80 (m, 2H); 2.0-2.20 (m, 4H); 2.85-2.96 (m, 2H); 3.20-3.40 (s, NH_2) 3.50 (s, 2H); 3.70 (s, 2H); 3.85 (s, 3H); 3.98 (s, 3H); 4.20-4.30 (m, 1H); 6.98 (d, J = 7.5 Hz, 1H, NH); 7.10 (d, J = 8.7 Hz, 2H); 7.20-7.35 (m, 4H); 7.42 (dd, J_1 = 9.2 Hz, J_2 = 2.5 Hz, 1H); 7.52 (d, J = 8.7 Hz, 2H); 7.74-7.77 (m, 2H).

The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

15 **Example 53:** (compounds 123)

53.1 {4-[(4-{[7-Methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}carboxylic acid (dihydrochloride)

20 3.1 mL of 2N sodium hydroxide and 5 mL of dichloromethane are added to a solution of 1.6 g (3.1 mmol) of methyl N-{4-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}carboxylate in 20 mL of methanol. The
25 mixture is stirred at room temperature for 20 hours and then acidified with 1N hydrochloric acid. It is evaporated under reduced pressure and the residue is

taken up in dichloromethane and ethanol. A white precipitate forms, which is washed with diisopropyl ether and then dried. 1.27 g of a white powder are obtained (72% yield).

5 m.p. = 295°C (Mettler FP62)

LC/MS: MH^+ = 499 (Rt = 5.12 minutes)

1H NMR δ in ppm (DMSO d_6): 2.15-2.50 (m, 4H); 3.0-3.20 (m, 2H); 3.40-3.60 (m, 2H); 3.89 (s, 3H); 4.09 (s, 3H); 4.20-4.30 (m, 1H); 4.40 (s, 2H); 7.21 (d, J = 8.5 Hz, 2H); 7.63 (d, J = 8.5 Hz, 2H); 7.72 (dd, J_1 = 9 Hz, J_2 = 2.2 Hz, 1H); 7.83 (d, J = 8.2 Hz, 2H); 7.93 (d, J = 9 Hz, 1H); 8.04 (d, J = 8.2 Hz, 2H); 8.46 (s, 1H); 11.16 (s, 1H, COOH); 13.17 (s, 1H, NH);.

15 **53.2 N-{4-[(4-{[7-Methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}carboxamide dihydrochloride**

0.29 mL (2.3 mmol) of N-ethylmorpholine is added to a stirred suspension of 400 mg (0.7 mmol) of {4-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}carboxylic acid (dihydrochloride) in 10 mL of tetrahydrofuran at 0°C, followed by dropwise addition of 0.074 mL (0.77 mmol) of ethyl chloroformate. The mixture is stirred for 1 hour at 0°C, and 0.6 mL (3.5 mmol) of a 20% aqueous ammonia solution is then added slowly. The reaction medium is stirred for 20 hours at room temperature and

is then concentrated under reduced pressure. 1N sodium hydroxide is added to the residue and the mixture is then extracted with dichloromethane. The organic phase is washed with saturated aqueous sodium chloride

5 solution, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The residue is purified on a column of silica (eluent: 85/15 (v/v) dichloromethane/methanol). 150 mg of a colourless oil are obtained.

10 LC/MS: $MH^+ = 498$ ($R_t = 4.88$ minutes)

1H NMR δ in ppm (DMSO d_6): 1.65-1.80 (m, 2H); 2.05-2.25 (m, 4H); 2.85-2.95 (m, 2H); 3.58 (s, 2H); 3.85 (s, 3H); 3.98 (s, 3H); 4.20-4.30 (m, 1H); 6.99 (d, $J = 7.3$ Hz, 1H, NH); 7.09 (d, $J = 6.7$ Hz, 2H); 7.30 (s, 1H); 7.40-
15 7.45 (m, 3H); 7.51 (d, $J = 6.7$ Hz, 2H); 7.72-7.76 (m, 2H); 7.86 (d, $J = 8.2$ Hz, 2H); 7.93 (s, 1H).

The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

20 **Example 54** (compounds 139)

1-{4-[(4-{[7-Methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino)piperidin-1-yl)methyl]phenyl}ethanol dihydrochloride

25 56 mg (1.2 mmol) of sodium borohydride are added to a suspension of 300 mg (0.6 mmol) of 1-{4-[(4-{[7-methoxy-4-(4-methoxyphenyl)phthalazin-1-

yl]amino)piperidin-1-yl)methyl]phenyl)ethanone
 (compound 121) in 6 mL of methanol. The mixture is
 stirred for 24 hours at room temperature and then for
 30 minutes at reflux. After cooling the reaction medium
 5 to 10°C, 1 mL of acetone is added and the mixture is
 then evaporated under reduced pressure. The residue is
 purified on a column of silica (eluent: 100/0 to 85/15
 (v/v) dichloromethane/methanol). 300 mg of a white
 powder are obtained.

10 LC/MS: $MH^+ = 499$ ($R_t = 5.06$ minutes)
 1H NMR δ in ppm (DMSO d_6): 1.07 (d, $J = 7$ Hz,
 3H); 1.65-1.80 (m, 2H); 2.05-2.25 (m, 4H); 2.85-2.95
 (m, 2H); 3.51 (s, 2H); 3.85 (s, 3H); 3.98 (s, 3H);
 4.20-4.30 (m, 1H); 4.68-4.77 (m, 1H); 5.10 (d, $J = 4.2$
 15 Hz, 1H, OH); 6.99 (d, $J = 7.5$ Hz, 1H, NH); 7.09 (d, $J =$
 8.7 Hz, 2H); 7.26-7.34 (m, 4H); 7.43 (dd, $J_1 = 9$ Hz, J_2
 = 2.5 Hz, 1H); 7.52 (d, $J = 8.7$ Hz, 2H); 7.73-7.77 (m,
 2H).

The dihydrochloride is obtained after treatment with a
 20 solution of hydrogen chloride in diethyl ether.

Example 55 (compounds 140)

**7-Methoxy-4-(4-methoxyphenyl)-N-{1-[4-(pyrrolidin-1-
 ylmethyl)benzyl]-piperidin-4-yl}phthalazin-1-amine
 25 trihydrochloride**

A solution of 360 mg (0.65 mmol) of 7-methoxy-4-(4-methoxyphenyl)-N-{1-[4-(pyrrolidin-1-yl-carboxy)benzyl]piperidin-4-yl}phthalazin-1-amine in 6 mL of tetrahydrofuran is stirred at 0°C, and 50 mg (1.3 mmol) of lithium aluminium hydride are added. The mixture is refluxed for 3 hours and then cooled and successively hydrolysed with 0.25 mL of water, 0.25 mL of 6N sodium hydroxide and 0.75 mL of water. The suspension obtained is filtered and evaporated under reduced pressure. The residue is purified on a column of silica (eluent: from 100/0 to 80/20 (v/v) dichloromethane/methanol). 40 mg of a white gummy product are obtained.

LC/MS: MH^+ = 538 (R_t = 4.50 minutes)

The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

Example 56 (compounds 151)

N-[1-(4-Dimethylaminomethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine trihydrochloride

A mixture of 400 mg (0.82 mmol) of N-[1-(4-aminomethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine and 0.2 mL (5 mmol) of formic acid is stirred at 0°C, and 0.32 mL (4.2 mmol) of aqueous 37% formaldehyde solution and 0.5 mL of

water are added. The reaction medium is stirred at 90°C for 8 hours and then at room temperature for 16 hours. 1N sodium hydroxide is added and the mixture is then extracted with dichloromethane. The organic phase is washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. The residue is purified using a resin of methyl isocyanate grafted onto polystyrene. 300 mg of product are obtained in the form of a yellow oil.

LC/MS: MH^+ = 512 (R_t = 4.43 minutes)

1H NMR δ in ppm (DMSO d_6): 1.65-1.80 (m, 2H); 2.00-2.15 (m, 4H); 2.15 (s, 6H); 2.85-2.95 (m, 2H); 3.37 (s, 2H); 3.51 (s, 2H); 3.85 (s, 3H); 3.98 (s, 3H); 4.20-4.30 (m, 1H); 6.99 (d, J = 7.6 Hz, 1H, NH); 7.09 (d, J = 8.5 Hz, 2H); 7.20-7.34 (m, 4H); 7.43 (dd, J_1 = 9 Hz, J_2 = 2.3 Hz, 1H); 7.52 (d, J = 8.5 Hz, 2H); 7.73-7.77 (m, 2H).

The trihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether.

Example 57 (compounds 94)

4-(4-Methoxyphenyl)-7-methoxy-N-[(3R)-1-(naphthalen-2-ylmethyl)pyrrolidin-3-yl]phthalazin-1-amine dihydrochloride

57.1 (3R)-1-(Naphthalen-2-ylmethyl)-3-tert-butylloxycarbonylaminopyrrolidine

This compound was prepared via the reductive amination method described in 49.2, by reaction of (R)-3-tert-butylloxycarbonylaminopyrrolidine with 2-naphthaldehyde.

5 The residue is purified on a column of silica (eluent: from 100/0 to 90/10 (v/v) dichloromethane/methanol).

LC/MS: $MH^+ = 327$ ($R_t = 6.34$ minutes)

1H NMR δ in ppm (DMSO d_6): 1.37 (m, 10H); 1.50-1.65 (m, 1H); 1.95-2.15 (m, 1H); 2.25-2.35 (m, 1H); 2.52 (m, 10 1H); 2.70-2.80 (m, 1H); 3.71 (s, 2H); 3.85-3.95 (m, 1H); 6.95 (d, 1H, NH); 7.45-7.55 (m, 3H); 7.80 (s, 1H); 7.85-7.95 (m, 3H).

57.2. (3R)-1-(Naphthalen-2-ylmethyl)pyrrolidin-3-ylamine
15

A solution of 2.5 g (7.66 mmol) of compound 57-1 in 25 mL of 2.5M HCl-EtOAc is heated at 80°C for 6 hours and then at room temperature for 16 hours. The reaction 20 medium is filtered. The precipitate is washed with ethyl acetate and then oven-dried. It is taken up in a mixture of dichloromethane and 1N sodium hydroxide, and then extracted with dichloromethane. The organic phase is washed with saturated aqueous sodium chloride 25 solution, dried over anhydrous sodium sulfate and then evaporated under reduced pressure.

LC/MS: $MH^+ = 227$ ($R_t = 2.71$ minutes)

^1H NMR δ in ppm (DMSO d_6): 1.35-1.45 (m, 1H); 1.50-1.85 (m, 1H); 1.95-2.15 (m, 1H); 2.15-2.20 (m, 1H); 2.45-2.75 (m, 4H); 3.30-3.40 (m, 1H); 3.65-3.8 (m, 2H); 7.4-7.55 (m, 3H); 7.80 (s, 1H); 7.85-7.95 (m, 3H).

5

57.3. 4-(4-Methoxyphenyl)-7-methoxy-N-[(3R)-1-(naphthalen-2-ylmethyl)pyrrolidin-3-yl]phthalazin-1-amine

10 This compound is obtained according to the method described in step 1.4 of Example 1, by reaction of (3R)-1-(naphthalen-2-ylmethyl)pyrrolidin-3-ylamine with 1-chloro-7-methoxy-4-(4-methoxyphenyl)phthalazine. The residue is purified on a column of silica (eluent: from 15 100/0 to 85/15 (v/v) dichloromethane/methanol).

LC/MS: $\text{MH}^+ = 491$ ($R_t = 5.93$ minutes)

The dihydrochloride is obtained after treatment with a solution of hydrogen chloride in diethyl ether

$[\alpha]_D^{20} = -50$ ($c=1$, MeOH)

20

Example 58 (compounds 96)

4-(4-Methoxyphenyl)-7-methoxy-N-[(3S)-1-(naphthalen-2-ylmethyl)pyrrolidin-3-yl]phthalazin-1-amine

25 **58.1. (3S)-1-(Naphthalen-2-ylmethyl)-3-tert-butyloxycarbonylamino-pyrrolidine**

This compound was obtained via the reductive amination method described in 49.2, by reaction of (S)-3-tert-butylloxycarbonylaminopyrrolidine with 2-naphthaldehyde.

5 The residue is purified on a column of silica (eluent: from 100/0 to 90/10 (v/v) dichloromethane/methanol).

LC/MS: MH^+ = 327 (Rt = 6.40 minutes)

1H NMR δ in ppm (DMSO d 6): 1.37 (m, 10H); 1.50-1.65 (m, 1H); 1.95-2.15 (m, 1H); 2.25-2.35 (m, 1H); 2.52 (m, 10 1H); 2.70-2.80 (m, 1H); 3.71 (s, 2H); 3.85-3.95 (m, 1H); 6.95 (d, 1H, NH); 7.45-7.55 (m, 3H); 7.80 (s, 1H); 7.85-7.95 (m, 3H).

58.2. (3S)-1-(Naphthalen-2-ylmethyl)pyrrolidin-3-ylamine

The deprotection of the amine was performed according to the method described in 57.2.

LC/MS: MH^+ = 227 (Rt = 2.89 minutes)

20 1H NMR δ in ppm (DMSO d 6): 1.35-1.45 (m, 1H); 1.50-1.85 (m, 1H); 1.95-2.15 (m, 1H); 2.15-2.20 (m, 1H); 2.45-2.75 (m, 4H); 3.30-3.40 (m, 1H); 3.65-3.8 (m, 2H); 7.40-7.55 (m, 3H); 7.80 (s, 1H); 7.85-7.95 (m, 3H).


25 **58.3. 4-(4-Methoxyphenyl)-7-methoxy-N-[(3S)-1-(naphthalen-2-ylmethyl)pyrrolidin-3-yl]phthalazin-1-amine**

This compound is obtained according to the method described in step 1.4 of Example 1, by reacting (3S)-1-(naphthalen-2-ylmethyl)pyrrolidin-3-ylamine with 1-
5 chloro-7-methoxy-4-(4-methoxyphenyl)phthalazine. The residue is purified on a column of silica (eluent: from 100/0 to 85/15 (v/v) dichloromethane/methanol).

LC/MS: $MH^+ = 491$ ($R_t = 5.93$ minutes)















The dihydrochloride is obtained after treatment with a
10 solution of hydrogen chloride in diethyl ether.

$[\alpha]_D^{20} = +47$ ($c=1$, MeOH)














Table














No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
1				H	H	OMe	H	H ₂ O (0.25/1)	121 (K)	475; Rt = 5.15
2				H	H	OMe	H	H ₂ O (0.75/1)	158 (M)	505; Rt = 5.16














No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
3				H	H	OMe	H	H ₂ O (0.25/1) iPr ₂ O (0.2/1)	195 (M)	505; Rt = 5.28
4				H	H	OMe	H	H ₂ O (0.25/1)	176 (M)	531; Rt = 5.43
5				H	H	OMe	H	H ₂ O (0.5/1)	154 (M)	505; Rt = 5.28
6				H	H	OMe	H	H ₂ O (0.25/1)	176 (M)	455; Rt = 4.80

No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
7				H	H	OMe	H	H ₂ O (0.25/1) iPr ₂ O (0.15/1)	150 (M)	455; Rt = 4.71
8				H	H	OMe	H	H ₂ O (0.3/1) iPr ₂ O (0.2/1)	115 (M)	431; Rt = 4.72
9				H	H	Me	H	H ₂ O (0.3/1)	198 (M)	489; Rt = 5.27
10				H	H	OMe	H	H ₂ O (0.5/1)	131 (K)	535; Rt = 5.13














No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
11				OMe	H	OMe	H	-	168 (K)	485; Rt = 4.82
12				H	H	OMe	H	H ₂ O (0.5/1)	209 (M)	457; Rt = 7.93
13			H	OMe	H	OMe	H	H ₂ O (0.5/1)	169 (M)	379; Rt = 4.05
14			H	OMe	H	OMe	H	H ₂ O (0.5/1)	206 (M)	429; Rt = 4.60
15				OMe	H	OMe	H	HCl (2/1) H ₂ O (1.5/1)	212 (K)	535; Rt = 5.26


























No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
16				H	H	OMe	H	H ₂ O (0.7/1) iPr ₂ O (0.1/1)	155 (M)	445; Rt = 5.02
17			H		H	OMe	H	H ₂ O (2/1) Et ₂ O (0.23/1)	199 (K)	475; Rt = 5.70
18				H	H	OMe	H	H ₂ O (0.5/1) iPr ₂ O (0.15/1)	115 (M)	480; Rt = 4.24
19				H	H	OMe	H	HCl (2/1) H ₂ O (1/1)	235 (B)	499; Rt = 5.31























No.			R_4	R_5	R_6	R_7	R_8	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H)+; Rt (minutes)
20			Et	H	H	OMe	H	H ₂ O (0.85/1)	135 (M)	427; Rt = 5.16
21				H	H	OMe	H	H ₂ O (0.7/1)	104 (M)	489; Rt = 5.71
22				OMe	H	OMe	H	-	163 (M)	519; Rt = 5.92
23			Et	OMe	H	OMe	H	H ₂ O (0.6/1)	250 (M)	457; Rt = 4.48
24			-CH ₂ -O-CH ₃	H	H	OMe	H	HCl (1/1) H ₂ O (1.2/1)	176 (M)	443; Rt = 4.01















No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
25				H	H	OMe	H	H ₂ O (0.25/1)	223 (M)	505; Rt = 4.77
26				H	H	OMe	H	H ₂ O (0.8/1)	160 (M)	495; Rt = 4.53
27				H	H	OMe	H	H ₂ O (0.5/1)	180 (M)	499; Rt = 4.39
28				H	H	OMe	H	H ₂ O (0.5/1)	212 (K)	523; Rt = 4.56

No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
29				H	H	OMe	H	H ₂ O (0.5/1)	130 (K)	483; Rt = 4.53
30				H	H	OMe	H	H ₂ O (0.5/1)	208 (K)	523; Rt = 4.83
31				H	H	OMe	H	H ₂ O (0.75/1)	122 (K)	508; Rt = 4.91
32				H	H	OMe	H	H ₂ O (0.75/1)	110 (K)	515; Rt = 4.44
















No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
33				H	H	OMe	H	H ₂ O (0.1/1)	154 (K)	439; Rt = 4.52
34				H	H	OMe	H	H ₂ O (0.8/1)	214 (K)	523; Rt = 10.08
35				H	H	OMe	H	H ₂ O (1/1) iPr ₂ O (0.3/1)	119 (K)	535; Rt = 4.90
36				H	H	OMe	H	H ₂ O (1.1/1)	130 (K)	527; Rt = 4.71

No.						R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
37						H	H	H	OMe	H	iPr ₂ O (0.15/1)	228 (K)	531; Rt = 5.17
38						H	H	H	OMe	H	-	236 (K)	511; Rt = 4.51
39						H	H	H	OMe	H	H ₂ O (0.5/1)	280 (M)	503; Rt = 4.68
40						H	H	H	OMe	H	H ₂ O (0.6/1)	228 (K)	513; Rt = 4.22













No.							R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
41					H	H	H	H	H	OMe	H	H ₂ O (0.6/1)	190 (K)	506; Rt = 4.20
42					H	H	H	H	H	OMe	H	HCl (2/1) H ₂ O (3.5/1)	272 (M)	519; Rt = 4.66
43					H	H	H	H	H	OMe	H	H ₂ O (1.5/1)	181 (M)	509; Rt = 5.22
44					H	H	H	H	H	OMe	H	H ₂ O (0.25/1)	265 (M)	535; Rt = 4.98














No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
45				H	H	OMe	H	H ₂ O (0.75/1)	230 (K)	543; Rt = 5.27
46				H	H	OMe	H	H ₂ O (0.5/1)	201 (M)	497; Rt = 4.64
47				H	H	OMe	H	H ₂ O (1/1)	200 (M)	535; Rt = 4.97
48				H	H	OMe	H	H ₂ O (0.25/1)	196 (M)	511; Rt = 4.84













No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
49			H	H	H	OMe	H	H ₂ O (0.35/1) iPr ₂ O (0.2/1)	149 (M)	483; Rt = 4.69
50			H	H	H	OMe	H	H ₂ O (0.55/1)	266 (M)	509; Rt = 4.82
51			H	H	H	OMe		HCl (2/1) H ₂ O (2.2/1)	244 (K)	467; Rt = 4.84
52			H	H	H	OMe		H ₂ O (0.5/1) iPr ₂ O (0.15/1)	152 (M)	469; Rt = 4.23











No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
53				H	H	OMe	H	H ₂ O (1.5/1)	212 (M)	531; Rt = 6.14
54				H	H	OMe		H ₂ O (0.9/1)	142 (M)	497; Rt = 5.41
55				H	H	OMe	H	H ₂ O (0.3/1)	162 (M)	495; Rt = 5.71
56				H	H	OMe	H	HCl (2/1) H ₂ O (3.6/1)	274 (M)	519; Rt = 5.87

No.			R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
57			H	H	OMe	H	H ₂ O (0.4/1) iPr ₂ O (0.2/1)	98 (M)	547; Rt = 5.34
58			H	H	OMe	H	H ₂ O (0.4/1) iPr ₂ O (0.04/1)	186 (M)	495; Rt = 4.74
59			H	H	OMe	H	H ₂ O (0.6/1) iPr ₂ O (0.02/1)	180 (K)	512; Rt = 5.24
60			H	H	OMe	H	H ₂ O (0.25/1) iPr ₂ O (0.04/1)	176 (K)	511; Rt = 5.69















No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
61				H	H	OMe	H	H ₂ O (1.8/1) iPr ₂ O (0.1/1)	118 (K)	495; Rt = 4.40
62				H	H	OMe	H	H ₂ O (1.3/1) iPr ₂ O (0.13/1)	114 (K)	495; Rt = 4.45
63				H	H	OMe	H	H ₂ O (0.7/1) iPr ₂ O (0.03/1)	172 (M)	536; Rt = 5.71
64				H	H	OMe	H	H ₂ O (0.2/1) iPr ₂ O (0.05/1)	176 (M)	501; Rt = 5.53















No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
65				H	H	OMe	H	H ₂ O (0.5/1) iPr ₂ O (0.07/1)	257 (M)	494; Rt = 4.82
66				H	H	OMe	H	H ₂ O (0.5/1) iPr ₂ O (0.01/1)	135 (M)	489; Rt = 5.16
67			nBut	H	H	OMe	H	H ₂ O (0.5/1)	101 (M)	455; Rt = 5.59
68				H	H	OMe	H	H ₂ O (0.5/1)	196 (M)	483; Rt = 5.50











No.								Salt and/or Solvates	m.p. (°C)	LC/MS (M+H)+; Rt (minutes)
69				H	H	OMe	H	HCl (2/1) H ₂ O (2.8/1)	210 (K)	481; Rt = 5.67
70			H	H	H	OMe	H	HCl (0.75/1) H ₂ O (0.2/1)	189 (M)	399; Rt = 3.78
71				H	H	OMe	H	-	n.d.	453; Rt = 4.45
72				H	H	OMe	H	-	172 (M)	541; Rt = 5.79














No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
73				H	H	OMe	H	-	190 (K)	557; Rt = 5.96
74				H	H	OMe	H	-	210 (M)	487; Rt = 5.53
75				H	H	OMe	H	HCl (0.75/1) iPr ₂ O (0.3/1)	148 (M)	469; Rt = 5.44
76				H	H	OMe	H	H ₂ O (0.5/1)	210 (M)	543; Rt = 6.07













No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
77				H	H	OMe	H	H ₂ O (0.65/1) iPr ₂ O (0.01/1)	124 (K)	506; Rt = 5.50
78				H	H	OMe	H	-	192 (M)	535; Rt = 5.72
79				H	H	OMe	H	-	168 (M)	507; Rt = 5.55
80				H	H	OMe	H	H ₂ O (0.4/1)	144 (M)	503; Rt = 5.41















No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
81				H	H	OMe	H	HCl (2/1) H ₂ O (2.3/1)	290 (M)	483; Rt = 5.55
82				H	H	OMe	H	H ₂ O (0.65/1)	175 (M)	493; Rt = 5.77
83				H	H	OMe	H	-	157 (M)	487; Rt = 5.51
84				H	H	OMe	H	-	186 (M)	541; Rt = 5.85












No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H)+; Rt (minutes)
85				H	H	OMe	H	H ₂ O (1/1)	163 (M)	510; Rt = 5.07
86				H	H	OMe	H	-	194 (M)	507; Rt = 5.58
87				H	H	OMe	H	H ₂ O (1,4/1) iPr ₂ O (0.3/1)	281 (M)	494; Rt = 5.32
88				H	H	OMe	H	H ₂ O (0.8/1) iPr ₂ O (0.3/1)	155 (M)	519; Rt = 5.68

No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
89			H	H	H	OMe	H	H ₂ O (2/1)	270 (M)	499; Rt = 5.55
90			H	H	H	OMe	H	H ₂ O (1.3/1) iPr ₂ O (0.2/1)	277 (M)	483; Rt = 5.63
91			H	H	H	OMe	H	H ₂ O (1.5/1) iPr ₂ O (0.2/1)	251 (M)	526; Rt = 5.41
92			H	H	H	OMe	H	H ₂ O (0.15/1)	277 (M)	518; Rt = 5.54

No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
93				H	H	OMe	H	H ₂ O (0.2/1)	175 (M)	491; Rt = 5.40
94 (R)				H	H	OMe	H	HCl (2/1) H ₂ O (3/1)	254 (M)	491; Rt = 5.96
95			Me	H	H	OMe	H	-	188 (M)	413; Rt = 4.96
96 (S)				H	H	OMe	H	HCl (2/1) H ₂ O (2.5/1)	280 (M)	491; Rt = 5.96
















No.					R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
97					H	H	OMe	H	HCl (2/1) H ₂ O (2.7/1) Et ₂ O (0.08/1)	240 (B)	535; Rt = 5.77
98					H	H	OMe	H	H ₂ O (0.5/1)	145 (M)	497; Rt = 5.66
99					H	H	OMe	H	H ₂ O (0.5/1)	249 (M)	506; Rt = 4.00














No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
100				H	H	OMe	H	H ₂ O (1.5/1)	161 (M)	508; Rt = 4.47
101				H	H	OMe	H	HCl (2/1) H ₂ O (3.5/1)	280 (M)	508; Rt = 5.64
102				H	H	OMe	H	HCl (2/1) H ₂ O (3/1)	228 (K)	535; Rt = 5.80
103				H	H	OMe	H	HCl (2/1) H ₂ O (2.7/1) Et ₂ O (0.06/1)	240 (B)	535; Rt = 5.93
















No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)	
104				H	H	H	OMe	H	HCl (2/1) H ₂ O (2.6/1)	264 (M)	503; Rt = 5.87
105				H	H	H	OMe	H	HCl (3/1) H ₂ O (2.5/1)	260 (K)	560; Rt = 4.87
106				H	H	H	F	H	-	207 (M)	481; Rt = 6.04













No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
107				H	H	OMe	H	HCl (2/1) H ₂ O (1.6/1)	241 (M)	513; Rt = 5.36
108				H	H	OMe	H	HCl (2/1) H ₂ O (2.5/1)	270 (M)	480; Rt = 5.23
109				H	H	OMe	H	HCl (2.6/1) H ₂ O (2.1/1)	225 (B)	476; Rt = 5.25
110				H	H	OMe	H	HCl (2/1) H ₂ O (2/1)	277 (M)	489; Rt = 5.51













No.			R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
111			H	H	OMe	H	HCl (2/1) H ₂ O (2.3/1)	292 (M)	551; Rt = 6.53
112			H	H	OMe	H	HCl (2/1) H ₂ O (2.5/1) Et ₂ O (0.25/1)	294 (M)	485; Rt = 4.98
113			H	H	OMe	H	HCl (3/1) H ₂ O (3.5/1)	284 (B)	484; Rt = 4.38
















No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
114				H	H	OMe	H	HCl (2/1) H ₂ O (2.5/1)	255 (B)	512; Rt = 5.04
115				H	H	OMe	H	H ₂ O (2/1)	104 (M)	495; Rt = 5.74
116				H	H	OMe	H	H ₂ O (0.35/1)	151 (M)	479; Rt = 5.68
117				H	H	OMe	H	HCl (2/1) H ₂ O (2/1)	210 (B)	503; Rt = 6.04













No.			R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
118			H	H	H	OMe	H	HCl (2/1) H ₂ O (1.7/1)	195 (M)	469; Rt = 5.44
119				H	H	OMe	H	HCl (0.6/1) iPr ₂ O (0.1/1)	228 (M)	486; Rt = 5.14
120				H	H	OMe	H	HCl (2/1) H ₂ O (1.6/1)	210 (B)	469; Rt = 5.44
121				H	H	OMe	H	HCl (2/1) H ₂ O (2.4/1) Et ₂ O (0.15/1)	241 (M)	497; Rt = 5.21













No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
122				H	H	OMe	H	HCl (2/1) H ₂ O (1.2/1)	296 (M)	489; Rt = 5.56
123				H	H	OMe	H	HCl (2/1) H ₂ O (4/1) Et ₂ O (0.3/1)	293 (M)	498; Rt = 4.88
124				H	H	OMe	H	HCl (2/1) H ₂ O (2/1)	250 (M)	525; Rt = 5.50
125				H	H	OMe	H	HCl (2/1) H ₂ O (2.3/1) iPr ₂ O (0.2/1)	272 (M)	529; Rt = 5.33

No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
126				H	H	OMe	H	HCl (2/1) H ₂ O (2.3/1)	224 (M)	509; Rt = 5.91
127				H	H	OMe	H	HCl (2/1) H ₂ O (2.5/1)	293 (M)	523; Rt = 5.21
128				H	H	OMe	H	HCl (3/1) H ₂ O (4.3/1) Et ₂ O (0.4/1)	272 (M)	506; Rt = 5.17

No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
129				H	H	OMe	H	H ₂ O (0.25/1)	278 (M)	494; Rt = 5.49
130				H	H	OMe	H	HCl (2/1) H ₂ O (2.5/1) Et ₂ O (0.15/1)	216 (K)	485; Rt = 5.34
131				H	H	OMe	H	HCl (2/1) H ₂ O (2/1)	291 (M)	503; Rt = 5.71

No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
132				H	H	OMe	H	HCl (1.7/1) H ₂ O (1/1)	245 (M)	483; Rt = 5.64
133				H	H	OMe	H	HCl (2/1) H ₂ O (2.7/1)	290 (M)	552; Rt = 5.21
134				H	H	OMe	H	HCl (2/1) H ₂ O (1.5/1) iPr ₂ O (0.4/1)	280 (M)	503; Rt = 5.71
135				H	H	OMe	H	H ₂ O (1/1)	193 (M)	542; Rt = 5.21

No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
136				H	H	OMe	H	HCl (2/1) H ₂ O (1.3/1)	239 (M)	505; Rt = 6.06
137				H	H		H	HCl (2/1) H ₂ O (1.8/1) Et ₂ O (0.25/1)	224 (M)	521; Rt = 6.48
138				H	H	OMe	H	-	267 (M)	495; Rt = 4.62

No.				R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
139				H	H	OMe	H	HCl (2/1) H ₂ O (1.8/1) Et ₂ O (0.2/1)	208 (K)	499; Rt = 5.07
140				H	H	OMe	H	HCl (3/1) H ₂ O (4.5/1)	222 (K)	538; Rt = 4.49
141				H	H	OMe	H	H ₂ O (0.3/1)	212 (M)	500; Rt = 5.32

No.				R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
142					H	Me	H	H	H ₂ O (0.2/1)	134 (M)	489; Rt = 5.72
143					H	H	Cl	H	HCl (2/1) H ₂ O (1.15/1)	230 (K)	509; Rt = 6.13
144					H	H	OMe	H	HCl (2/1) H ₂ O (1.3/1)	289 (M)	549; Rt = 5.76
145					H	H	OMe	H	HCl (2/1) H ₂ O (0.6/1) Et ₂ O (0.14/1)	246 (M)	555; Rt = 6.13

No.				R ₄	R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
146				-CH ₂ -O-CH ₃	H	H	OMe	H	HCl (2/1) H ₂ O (1/1)	284 (M)	437; Rt = 4.48
147					H	H	OMe	H	HCl (2/1) Et ₂ O (0.23/1)	284 (M)	519; Rt = 5.87
148				-CH ₂ -OH	H	H	OMe	H	HCl (2/1) H ₂ O (2.8/1)	186 (K)	429; Rt = 4.76
149 (-)					H	H	OMe	H	Isorexane (0.5/1) H ₂ O (1.7/1)	136 (M)	519; Rt = 5.76

No.			R ₅	R ₆	R ₇	R ₈	Salt and/or Solvates	m.p. (°C)	LC/MS (M+H) ⁺ ; Rt (minutes)
150 (+)			H	H	OMe	H	Isohexane (0.4/1) H ₂ O (2.2/1)	132 (M)	519; Rt = 5.76
151			H	H	OMe	H	HCl (3/1) H ₂ O (4.5/1) Et ₂ O (0.3/1)	218 (K)	512; Rt = 4.40

The compounds according to the invention underwent pharmacological tests. Their affinity towards the receptor 1 of Melamin-Concentrating Hormone (MCH), MCH₁ was determined by these means.

5 The tests consisted in measuring the *in vitro* activity of the compounds of the invention on the MCH₁ receptors of MCH.

Binding studies

10 The measurement of the affinity of the compounds of the invention for the MCH receptors was performed by studying the displacement of the binding of a radiolabelled derivative of MCH to the MCH₁ receptors. This study was performed on rat and/or mouse brain membrane preparations
15 according to the protocol described below.

 In anticipation of the binding studies, the brains are diluted in HEPES buffer 25 mM (pH: 7.4) containing MgCl₂ 5 mM, CaCl₂ 1 mM, homogenized using a Polytron blender for 3 times 20 seconds (speed 25), and are then ultracentrifuged
20 at 22 000 rpm and at +4°C for 30 minutes. The centrifugation pellet is taken up in the same buffer and the membranes are divided into aliquots and stored frozen at -80°C until the time of use.

 The membranes are warmed to room temperature and
25 then incubated in the presence of the test compounds, and of 50 pM of an MCH-based radiolabelled molecule, [¹²⁵I]-Tyr-S36057 (8-amino-3,6-dioxyoctanoyl MCH 6-17 sold by Perkin-Elmer), in HEPES buffer 25 mM (pH: 7.4) containing MgCl₂ 5 mM, CaCl₂ 1 mM, bacitracin 140 mg/L, phenanthroline 1 mM

and 0.2% bovine serum albumin. The incubation is performed at room temperature for 30 minutes, and then stopped by rapid addition of ice-cold HEPES buffer 25 mM (pH: 7.4) supplemented with 0.2% bovine serum albumin, and by
5 filtration through GF/B glass fibre filters preincubated for 2 hours in an aqueous 0.1% polyethyleneimine solution. The radioactivity retained on the filters is measured using a Gamma scintillation counter. The non-specific binding is determined in the presence of 1 μ M of non-radiolabelled
10 S36057. The specific binding is obtained by difference between the total binding and the non-specific binding. The inhibitory activity of the compounds of the invention is expressed by means of the concentration that inhibits 50% of the specific binding (IC_{50}).

15 Within the scope of the invention, the IC_{50} values of the compounds are generally less than 10 μ M.

 The compounds of formula (I) advantageously have IC_{50} values of less than 1 μ M, more advantageously less than or equal to 100 nM and even more advantageously less than or
20 equal to 10 nM.


 By way of example:

- the compound according to Example 42 has an IC_{50} of 360 nM;
- the compound according to Example 2 has an IC_{50} of 72 nM;
- the compound according to Example 4 has an IC_{50} of 3 nM.

25 The compounds according to the invention may be used for the preparation of medicinal products, in particular medicinal products that are antagonists of the MCH_1 receptor of MCH.

CLAIMS

1. Compound corresponding to general formula (I)



5

- A represents a C₁₋₄-alkylene group optionally substituted with one or more groups R₉, which may be identical or different;
- B represents a C₁₋₄-alkylene group optionally substituted
10 with one or more groups R₁₀, which may be identical or different;
- R₉ and R₁₀ each represent, independently of each other, a hydrogen atom or a C₁₋₅-alkyl group, or alternatively R₉ and R₁₀ together form a single bond or a C₁₋₄-alkylene group;
- 15 • L represents a single bond or a C₁₋₂-alkylene, -CH=CH- or -C≡C- group; the C₁₋₂-alkylene and -CH=CH- groups being optionally substituted with one or more C₁₋₂-alkyl substituents; or alternatively L represents a cycloprop-1,2-diyl group;
- 20 • R₁ represents an aryl or a heteroaryl; the aryl and heteroaryl groups being optionally substituted with one or more radicals Z, which may be identical or different;

- R_2 and R_3 represent, independently of each other, a hydrogen atom or a C_{1-3} -alkyl or C_{1-3} -fluoroalkyl group,
 . or alternatively R_2 and R_3 form, together with the carbon atom that bears them, a cycloprop-1,1-diyl group;
- 5 • R_4 represents a hydrogen atom or a C_{1-5} -alkyl, C_{1-3} -fluoroalkyl, C_{3-6} -cycloalkyl, C_{3-6} -cycloalkyl- C_{1-3} -alkylene, C_{1-3} -alkyl-O- C_{1-3} -alkylene, HO- C_{1-3} -alkylene or C_{1-3} -alkyl-X- C_{1-3} -alkylene group in which X represents S, SO or SO_2 ,
- 10 . or alternatively R_4 represents an R_aR_bN - C_{1-3} -alkylene, aryl, aryl- C_{1-3} -alkylene, aryl-O-, aryl-O- C_{1-3} -alkylene, aryl- C_{1-3} -alkylene-O- C_{1-3} -alkylene, heteroaryl or heteroaryl- C_{1-3} -alkylene group; the aryl, aryl- C_{1-3} -alkylene, aryl-O-, aryl-O- C_{1-3} -alkylene, heteroaryl and heteroaryl- C_{1-3} -alkylene
- 15 groups being optionally substituted with one or more radicals Z, which may be identical or different;
- R_5 represents a hydrogen or halogen atom or a C_{1-5} -alkyl, C_{1-3} -fluoroalkyl, C_{1-5} -alkoxy, C_{1-3} -fluoroalkoxy, HO- C_{1-3} -alkylene, -CN or C_{1-3} -alkyl-X- group in which X represents S,
- 20 SO or SO_2 ,
- . or alternatively R_5 represents an R_aR_bN -, R_aR_bN - C_{1-3} -alkylene, aryl, aryl- C_{1-3} -alkylene, aryl-O- or heteroaryl group; the aryl, aryl- C_{1-3} -alkylene, aryl-O- and heteroaryl groups being optionally substituted with one or more
- 25 radicals Z, which may be identical or different;
- R_6 represents a hydrogen or halogen atom or a C_{1-5} -alkyl, C_{1-3} -fluoroalkyl, C_{1-5} -alkoxy, C_{1-3} -fluoroalkoxy, -CN, R_aR_bN -, R_aR_bN - C_{1-3} -alkylene, aryl or heteroaryl group; the aryl and

heteroaryl groups being optionally substituted with one or more radicals Z, which may be identical or different;

- R₇ represents a hydrogen or halogen atom or a C₁₋₅-alkyl, C₁₋₃-fluoroalkyl, C₁₋₅-alkoxy, C₁₋₃-fluoroalkoxy, HO-C₁₋₃-alkylene, -CN or C₁₋₃-alkyl-X- group in which X represents S, SO or SO₂; or alternatively R₇ represents an R_aR_bN-, R_aR_bN-C₁₋₃-alkylene, R_aR_bNC(O)-, C₁₋₃-alkyl-C(O)-, aryl, aryl-O- or heteroaryl group; the aryl, aryl-O- and heteroaryl groups being optionally substituted with one or more radicals Z, which may be identical or different;

- R₈ represents a hydrogen or halogen atom or a C₁₋₅-alkyl, C₁₋₅-alkoxy or C₁₋₃-fluoroalkoxy group;
- Z represents a hydrogen or halogen atom or a C₁₋₅-alkyl, C₁₋₃-fluoroalkyl, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₃-alkylene, phenyl, C₁₋₅-alkoxy, C₁₋₃-fluoroalkoxy, C₁₋₃-alkyl-O-C₁₋₃-alkylene, HO-C₁₋₃-alkylene, NO₂, -CN, C₁₋₃-alkyl-X- or C₁₋₃-alkyl-X-C₁₋₃-alkylene group in which X represents S, SO or SO₂,

. or alternatively Z represents an R_aR_bN-, R_aR_bN-C₁₋₃-alkylene, R_aR_bNC(O)-, C₁₋₃-alkyl-C(O)-, C₁₋₄-alkyl-CO₂- or C₃₋₆-cycloalkyl-C(O)- group,

. or alternatively Z represents an oxo radical,

. or alternatively two adjacent radicals Z together form a C₁₋₃-alkylenedioxy group;

- R_a and R_b each represent, independently of each other, a hydrogen atom or a C₁₋₃-alkyl or C₁₋₃-alkyl-C(O)- group; or alternatively R_a and R_b form, together with the nitrogen atom that bears them, a heterocycle optionally substituted with one or more C₁₋₃-alkyl or oxo groups;

it being understood that when R_2 , R_3 , R_5 , R_6 , R_7 and R_8 all represent a hydrogen atom, A and B both represent an ethylenyl group ($-\text{CH}_2\text{CH}_2-$) and L is a single bond, R_1 and R_4 cannot both represent an unsubstituted phenyl group;

5 in the form of base or of acid-addition salt, and also in the form of hydrate or solvate, and also the enantiomers and diastereoisomers thereof, and mixtures thereof.

2. Compound of formula (I) according to Claim 1, characterized in that:

- A represents a C_{1-4} -alkylene group optionally substituted with one or more groups R_9 , which may be identical or different;
- B represents a C_{1-4} -alkylene group optionally substituted
- 15 with one or more groups R_{10} , which may be identical or different;
- R_9 and R_{10} each represent a hydrogen atom, or alternatively R_9 and R_{10} together form a C_{1-4} -alkylene group;
- L represents a single bond or $-\text{CH}=\text{CH}-$;
- 20 • R_1 represents an aryl or a heteroaryl; the aryl and heteroaryl groups being optionally substituted with one or more radicals Z, which may be identical or different;
- R_2 and R_3 represent, independently of each other, a hydrogen atom or a C_{1-3} -alkyl group;
- 25 • R_4 represents a hydrogen atom or a C_{1-5} -alkyl, C_{3-6} -cycloalkyl, C_{3-6} -cycloalkyl- C_{1-3} -alkylene, C_{1-3} -alkyl-O- C_{1-3} -alkylene, aryl, aryl- C_{1-3} -alkylene, aryl- C_{1-3} -alkylene-O- C_{1-3} -alkylene, heteroaryl or heteroaryl- C_{1-3} -alkylene group; the aryl, aryl- C_{1-3} -alkylene, heteroaryl and heteroaryl- C_{1-3} -

alkylene groups being optionally substituted with one or more radicals Z, which may be identical or different;

- R_5 represents a hydrogen atom or a C_{1-5} -alkyl, C_{1-5} -alkoxy or aryl group; the aryl group being optionally substituted
- 5 with one or more radicals Z, which may be identical or different;
- R_6 represents a hydrogen atom;
- R_7 represents a halogen atom or a C_{1-5} -alkyl or C_{1-5} -alkoxy group or an aryl;
- 10 • R_8 represents a hydrogen atom;
- Z represents a hydrogen or halogen atom or a C_{1-5} -alkyl, C_{1-3} -fluoroalkyl, C_{3-6} -cycloalkyl, C_{3-6} -cycloalkyl- C_{1-3} -alkylene, phenyl, C_{1-5} -alkoxy, C_{1-3} -fluoroalkoxy, C_{1-3} -alkyl-O- C_{1-3} -alkylene, HO- C_{1-3} -alkylene, NO_2 , -CN, C_{1-3} -alkyl-X- or
- 15 C_{1-3} -alkyl-X- C_{1-3} -alkylene group in which X represents S, SO or SO_2 ,

. or alternatively Z represents an R_aR_bN -, R_aR_bN - C_{1-3} -alkylene, $R_aR_bNC(O)$ -, C_{1-3} -alkyl-C(O)- or C_{3-6} -cycloalkyl-C(O)-group,

- 20 . or alternatively Z represents an oxo radical,
- . or alternatively two adjacent radicals Z together form a C_{1-3} -alkylenedioxy group;
- R_a and R_b each represent, independently of each other, a hydrogen atom or a C_{1-3} -alkyl or C_{1-3} -alkyl-C(O)- group,
- 25 . or alternatively R_a and R_b form, together with the nitrogen atom that bears them, a heterocycle optionally substituted with one or more C_{1-3} -alkyl or oxo groups;

in the form of base or of acid-addition salt, and also in the form of hydrate or solvate, and also the enantiomers and diastereoisomers thereof, and mixtures thereof.

3. Compound of formula (I) according to either
5 of Claims 1 and 2, characterized in that:

- A represents a C₁₋₄-alkylene group optionally substituted with a group R₉;
- B represents a C₁₋₄-alkylene group optionally substituted with a group R₁₀;
- 10 • R₉ and R₁₀ each represent a hydrogen atom or R₉ and R₁₀ together form a C₁₋₄-alkylene group;
- L represents a single bond or -CH=CH-;
- R₁ represents an aryl optionally substituted with one or more radicals Z, which may be identical or different;
- 15 • R₂ and R₃ represent, independently of each other, a hydrogen atom or a C₁₋₃-alkyl group;
- R₄ represents a hydrogen atom or a C₁₋₅-alkyl, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₃-alkylene, C₁₋₃-alkyl-O-C₁₋₃-alkylene, aryl or heteroaryl group; the aryl and heteroaryl
20 groups being optionally substituted with one or more radicals Z, which may be identical or different;
- R₅ represents a hydrogen atom;
- R₆ represents a hydrogen atom;
- R₇ represents a halogen atom, a methyl or a methoxy;
- 25 • R₈ represents a hydrogen atom;
- Z represents a hydrogen atom, a halogen atom or a C₁₋₅-alkyl, C₁₋₅-alkoxy, C₁₋₃-alkyl-O-C₁₋₃-alkylene, phenyl, HO-C₁₋₃-alkylene, -CN or C₁₋₃-alkyl-X- group in which X represents a sulfur atom,

. or alternatively Z represents an R_aR_bN- , $R_aR_bN-C_{1-3}-$ alkylene, $R_aR_bNC(O)-$ or C_{1-3} -alkyl- $C(O)-$ group,

. or alternatively Z represents an oxo radical,

. or alternatively two adjacent radicals Z together
5 form a C_{1-3} -alkylenedioxy group;

• R_a and R_b each represent, independently of each other, a hydrogen atom or a C_{1-3} -alkyl or C_{1-3} -alkyl- $C(O)-$ group; in the form of base or of acid-addition salt, and also in the form of hydrate or solvate, and also the enantiomers and
10 diastereoisomers thereof, and mixtures thereof.

4. Compounds of formula (I) according to Claim 1, chosen from:

- 7-methoxy-4-(4-methoxyphenyl)-N-[8-(2-naphthylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]phthalazin-1-amine;
- 15 • 7-methoxy-4-(4-methoxyphenyl)-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine;
- 7-methoxy-4-(3-methoxyphenyl)-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 7-methoxy-4-(2-methoxyphenyl)-N-[1-(2-naphthyl-
20 methyl)piperidin-4-yl]phthalazin-1-amine;
- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-phenylphthalazin-1-amine;
- 4-(4-methoxyphenyl)-7-methyl-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 25 • 4-(3,4-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride;

- 4-ethyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 4-benzyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 5 • 7-methoxy-4-(methoxymethyl)-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine hydrochloride;
- N-[1-(1-benzofuran-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- N-[1-(3,4-dimethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-
- 10 methoxyphenyl)phthalazin-1-amine;
- 7-methoxy-4-(4-methoxyphenyl)-N-[1-[(1-methyl-1H-indol-2-yl)methyl]piperidin-4-yl]phthalazin-1-amine;
- 4-cyclopropyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 15 • N-[1-(3-fluoro-4-methoxybenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- N-[1-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 4-(1,3-benzodioxol-5-yl)-7-methoxy-N-[1-(2-naphthyl-
- 20 methyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- 4-(4-chlorophenyl)-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine;
- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-[4-(trifluoromethyl)phenyl]phthalazin-1-amine;
- 25 • N-[1-(1-benzothien-2-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 4-cyclopentyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride;


- N-[1-(2,3-dihydro-1-benzofuran-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- N-[1-(2,3-dihydro-1H-inden-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 5 • 7-methoxy-4-(4-methoxyphenyl)-N-{1-[1-(2-naphthyl)-ethyl]piperidin-4-yl}phthalazin-1-amine dihydrochloride;
- N-[1-(1,3-benzothiazol-6-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- N-[1-(1-benzothien-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-
- 10 (4-methoxyphenyl)phthalazin-1-amine;
- N-[1-(1H-indol-3-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 7-methoxy-4-(4-methylphenyl)-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 15 • 4-butyl-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 7-methoxy-4-(4-methoxyphenyl)-N-{1-[(2E)-3-phenylprop-2-en-1-yl]piperidin-4-yl}phthalazin-1-amine dihydrochloride;
- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-
- 20 phthalazin-1-amine;
- 4-(cyclopropylmethyl)-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine;
- N-[1-(3-fluoro-4-methylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 25 • 7-methoxy-4-(4-methoxyphenyl)-N-[1-(4-methylbenzyl)-piperidin-4-yl]phthalazin-1-amine;
- 4-(4-fluorophenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine (compound No. 82);

- N-[1-(1H-indol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 7-methoxy-4-[4-(methoxymethyl)phenyl]-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 5 • 7-methoxy-N-[1-(4-methoxy-3-methylbenzyl)piperidin-4-yl]-4-(4-methoxyphenyl)phthalazin-1-amine;
- 7-methoxy-4-methyl-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 4-(2,5-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- 10 • 7-methoxy-4-(4-methoxyphenyl)-N-[1-(quinolin-6-ylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 7-methoxy-4-(4-methoxyphenyl)-N-{1-[(1-methyl-1H-indol-5-yl)methyl]piperidin-4-yl}phthalazin-1-amine;
- 15 • 4-(2,4-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- 4-(3,5-dimethoxyphenyl)-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-(2-phenylethyl)phthalazin-1-amine dihydrochloride;
- 20 • 4-{4-[(diethylamino)methyl]phenyl}-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine trihydrochloride;
- 7-fluoro-4-(4-fluorophenyl)-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine;
- 25 • 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-pyridin-3-ylphthalazin-1-amine trihydrochloride;
- N-[1-(4-chlorobenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride;

- {4-[(4-{ [7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}methanol dihydrochloride;
- N-{1-[4-(aminomethyl)benzyl]piperidin-4-yl}-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine trihydrochloride;
- 5 • N-{4-[(4-{ [7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}acetamide dihydrochloride;
- 1-{4-[(4-{ [7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]phenyl}ethanone dihydrochloride;
- 10 • N-[1-(1-benzofuran-5-ylmethyl)piperidin-4-yl]-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazin-1-amine dihydrochloride;
- 15 • N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazin-1-amine dihydrochloride;
- 6-[(4-{ [7-methoxy-4-(4-methoxyphenyl)phthalazin-1-yl]amino}piperidin-1-yl)methyl]-2H-chromen-2-one dihydrochloride;
- 20 • N-[1-(1H-indol-6-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 7-methoxy-N-[1-(4-methoxybenzyl)piperidin-4-yl]-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride;
- 25 • N-[1-(4-ethylbenzyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine dihydrochloride;
- N-[1-(1,3-benzothiazol-6-ylmethyl)piperidin-4-yl]-4-(2,5-dimethoxyphenyl)-7-methoxyphthalazin-1-amine;

- 7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]-4-(phenoxymethyl)phthalazin-1-amine dihydrochloride;
- N-[1-(1H-benzimidazol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine;
- 5 • 7-chloro-4-(4-methoxyphenyl)-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- 4-(4-bromophenyl)-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-methoxy-4-(methoxymethyl)phthalazin-1-amine
- 10 dihydrochloride;
- 4-[(benzyloxy)methyl]-7-methoxy-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- 7-methoxy-5-phenyl-N-[1-(2-naphthylmethyl)piperidin-4-yl]phthalazin-1-amine dihydrochloride;
- 15 • 4-(hydroxymethyl)-7-methoxy-N-[1-(2-naphthylmethyl)-piperidin-4-yl]-4-(phenoxymethyl)phthalazin-1-amine;
- (-)-7-methoxy-4-(4-methoxyphenyl)-N-{1-[1-(2-naphthyl)-ethyl]piperidin-4-yl}phthalazin-1-amine;
- 20 • (+)-7-methoxy-4-(4-methoxyphenyl)-N-{1-[1-(2-naphthyl)-ethyl]piperidin-4-yl}phthalazin-1-amine;
- N-{1-[4-(dimethylaminomethyl)benzyl]piperidin-4-yl}-7-methoxy-4-(4-methoxyphenyl)phthalazin-1-amine trihydrochloride.

25 5. Process for preparing a compound of formula (I) according to any one of Claims 1 to 4, characterized in that a compound of general formula (III)




(III)

in which R_4 , R_5 , R_6 , R_7 and R_8 are as defined in the general formula (I) according to Claim 1,

is reacted with a compound of general formula (II)

5




(II)


in which R_1 , R_2 , R_3 , L , A and B are as defined in the general formula (I) according to Claim 1.

6. Compound of formula (V), (IV) and (III):


10



(V)



(IV)



(III)

in which R_4 , R_5 , R_6 , R_7 and R_8 are as defined in the general
15 formula (I) according to Claim 1.

7. Medicinal product, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 4, or a pharmaceutically acceptable acid-addition salt of this compound, or alternatively a hydrate
5 or a solvate of the compound of formula (I).

8. Pharmaceutical composition, characterized in that it comprises at least one compound of formula (I) according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound,
10 and also at least one pharmaceutically acceptable excipient.

9. Use of a compound of formula (I) according to any one of Claims 1 to 4, for the preparation of a medicinal product for treating any disease involving dysfunction associated with the MCH₁ receptor.

15 10. Use of a compound of formula (I) according to any one of Claims 1 to 4, for the preparation of a medicinal product for treating obesity, cellulitis, metabolic disorders and associated pathologies thereof such as diabetes, cardiovascular disorders and syndrome X, and in
20 the treatment of stress-related pathologies such as anxiety and depression.